ÔªøOlfactory Ensheathing Cell Transplantation	1
a Complete Spinal Cord Transection	53
Neuroprotective and Immunomodulatory Mechanisms	97
Regeneration Multiple neural	159
Regeneration	159
peripheral cell types	193
tissue damage after spinal cord injury	234
tissue damage	234
spinal cord injury	254
a structurally and chemically inhibitory scar that limits axon regeneration	281
a structurally and chemically inhibitory scar	281
axon regeneration	339
Astrocytes	358
an astroglial scar	374
chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	405
chondroitin sulfate proteoglycans	405
CSPGs	440
microglia	457
blood-derived immune cells	480
the lesion for debris removal	510
the lesion	510
debris removal	525
One beneficial therapy	541
olfactory ensheathing cell -LRB- OEC -RRB- transplantation	565
olfactory ensheathing cell	565
OEC	593
transplantation	598
functional improvements	626
axon regeneration	663
spinal cord injury	687
The lack of an OEC-specific marker	707
The lack	707
an OEC-specific marker	719
the investigation of mechanisms underlying their proregenerative effects	764
the investigation	764
mechanisms underlying their proregenerative effects	785
mechanisms	785
their proregenerative effects	807
We	838
the effects of enhanced green fluorescent protein-labeled fibroblast	850
the effects	850
enhanced green fluorescent protein-labeled fibroblast	865
FB	920
OEC transplants	928
a complete low-thoracic spinal cord transection	958
the preservation	1031
neurons and serotonergic axons	1051
neurons	1051
serotonergic axons	1063
the levels of inhibitory CSPGs and myelin debris	1083
the levels	1083
inhibitory CSPGs and myelin debris	1097
inhibitory CSPGs	1097
myelin debris	1118
the extent of immune cell activation between 1 and 8	1137
the extent	1137
immune cell activation between 1 and 8	1151
immune cell activation	1151
1 and 8	1182
Our findings	1208
OECs	1235
FBs post-transplantation	1260
FBs	1260
axons and neurons	1295
inhibitory molecules	1325
the lesion core	1349
we	1380
OECs	1393
immune-cell activation and infiltration	1404
FBs	1453
astroglial scar formation and increase immune-cell infiltration	1463
concomitant secondary tissue damage	1531
Administration of cyclosporine-A to enhance graft survival	1568
Administration	1568
cyclosporine-A to enhance graft survival	1586
graft survival	1612
immune suppression	1645
OEC contact-mediated protection of axons and neurons	1676
OEC contact-mediated protection	1676
axons and neurons	1711
the first 2 weeks postinjury	1736
these data	1780
OECs	1804
neuroprotective and immunomodulatory mechanisms	1814
a supportive environment for neuronal survival and axon regeneration	1874
a supportive environment	1874
neuronal survival and axon regeneration	1903
spinal cord injury	1949
Significance Statement Spinal cord injury	1970
Significance Statement	1970
Spinal cord injury	1993
physical and chemical barriers	2020
a complete spinal cord transection model and olfactory ensheathing cell	2079
OEC	2152
fibroblast -LRB- FB ; control -RRB-	2160
fibroblast	2160
FB ; control	2172
FB	2172
control	2176
transplantation as a repair strategy	2185
transplantation	2185
a repair strategy	2204
OECs , but not FBs , intermingled with astrocytes ,	2223
OECs	2223
FBs , intermingled with astrocytes	2237
FBs	2237
astrocytes	2260
astroglial scar border formation and sequestered	2284
astroglial scar border formation	2284
sequestered	2321
peripheral cells	2342
OECs	2360
immune cell infiltration	2376
secondary tissue damage	2410
neurons and axons	2445
the lesion core	2466
clear myelin debris	2494
Immunosuppression	2515
survival of OECs and FBs	2542
survival	2542
OECs and FBs	2554
OEC transplantation	2577
scaffold formation	2606
the lesion site that facilitated axon regeneration and neuron preservation	2628
the lesion site	2628
axon regeneration and neuron preservation	2661
axon regeneration	2661
neuron preservation	2683
Introduction	2705
The regenerative capacity	2718
adult mammalian neurons	2747
injury	2777
astroglial scar formation	2798
inhibitory myelinassociated proteins	2825
chondroitin sulfate proteoglycan -LRB- CSPG -RRB- deposition	2863
chondroitin sulfate proteoglycan	2863
CSPG	2897
deposition	2903
inflammatory cell activation	2919
a nonpermissive environment and minimal functional recovery	2976
a nonpermissive environment	2976
minimal functional recovery	3008
Reier	3037
Houle , 1988	3047
Houle	3047
1988	3054
Fitch et al. , 1999	3060
Fitch	3060
et al. , 1999	3066
et al.	3066
1999	3074
Fitch and Silver , 2008	3080
Fitch and Silver	3080
2008	3098
Buss et al. , 2009 ; Hu et al. ,	3104
Buss	3104
et al. , 2009 ; Hu et al. ,	3109
et al.	3109
2009 ; Hu et al.	3117
2009	3117
Hu et al.	3123
Hu	3123
et al.	3126
2010	3134
axonal regeneration and subsequent synaptic connectivity	3155
axonal regeneration	3155
subsequent synaptic connectivity	3179
therapies	3213
these post-traumatic growth-inhibitory factors	3237
tissue preservation	3296
Examples of such therapies	3317
Examples	3317
such therapies	3329
the reduction of glial scar inhibition	3352
the reduction	3352
glial scar inhibition	3369
the removal of cellular debris	3392
the removal	3392
cellular debris	3407
the establishment of a permissive cellular bridge across the lesion site	3428
the establishment	3428
a permissive cellular bridge across the lesion site	3449
a permissive cellular bridge	3449
the lesion site	3485
treatments	3516
neurotrophic factors	3540
spared neurons and function in axonal guidance	3564
spared neurons and function	3564
axonal guidance	3595
the intrinsic capacity of injured neurons	3623
the intrinsic capacity	3623
injured neurons	3649
functional synaptic connections	3679
recovery	3724
an olfactory nerve injury	3740
olfactory ensheathing cells -LRB- OECs -RRB-	3767
olfactory ensheathing cells	3767
OECs	3796
the generation of new olfactory receptor neurons	3813
the generation	3813
new olfactory receptor neurons	3831
a conduit	3875
they	3918
their olfactory bulb targets	3934
Lipson	3964
et al. , 2003 ; Li et al. , 2005a	3971
et al.	3971
2003 ; Li et al.	3979
2003	3979
Li et al.	3985
Li	3985
et al.	3988
2005a	3996
OECs	4004
adhesion molecules involved in axonal outgrowth	4017
adhesion molecules	4017
axonal outgrowth	4048
trophic factors , such as brain derived	4074
trophic factors	4074
brain derived	4099
brain	4099
neurotrophic factor and ciliary neurotrophic factor	4113
CNTF	4166
ensheath growing axons to protect them from inhibitory molecules	4177
ensheath	4177
axons	4194
them	4211
inhibitory molecules	4221
the past decade	4248
many studies	4265
OECs	4292
axon regeneration	4305
a severe spinal cord injury	4334
rodents and humans	4365
Ramo ¬	4385
Ramo	4385
et al. , 1998 , 2000 ;	4400
et al.	4400
1998	4408
2000	4414
et al. , 2002 ; Lo ¬ ¥ pez-Vales et al. , 2006 ;	4423
et al.	4423
2002 ; Lo ¬ ¥ pez-Vales et al. , 2006 ;	4431
2002	4431
Lo ¬ ¥ pez-Vales et al. , 2006	4437
Lo ¬ ¥ pez-Vales	4437
Lo	4437
¥ pez-Vales	4440
et al. , 2006	4452
et al.	4452
2006	4460
et al. , 2008 ; Takeoka et al. , 2011 ; Ziegler et al. ,	4474
et al.	4474
2008 ; Takeoka et al. , 2011 ; Ziegler et al. ,	4482
2008	4482
Takeoka et al. , 2011 ; Ziegler et al. ,	4488
Takeoka	4488
et al. , 2011 ; Ziegler et al. ,	4496
et al.	4496
2011 ; Ziegler et al.	4504
2011	4504
Ziegler et al.	4510
Ziegler	4510
et al.	4518
Granger et al. , 2012 ; Tabakow et al. , 2014	4532
Granger et al. , 2012 ; Tabakow et al. ,	4532
Granger	4532
et al.	4540
2012 ; Tabakow et al.	4548
2012	4548
Tabakow et al.	4554
Tabakow	4554
et al.	4562
2014	4570
these studies	4590
anatomical	4619
behavioral evidence	4650
OEC transplantation	4675
the regeneration of corticospinal tract axons	4704
the regeneration	4704
corticospinal tract axons	4724
neurons and axons near the lesion site	4761
neurons and axons	4761
the lesion site	4784
the recovery of motor-evoked potentials	4811
the recovery	4811
motor-evoked potentials	4827
the hindlimb muscles	4854
grid climbing ability compared with media-treated controls	4905
grid climbing ability	4905
media-treated controls	4941
these functional improvements	4973
the lack of an OEC-specific marker	5004
the lack	5004
an OEC-specific marker	5016
the irrefutable identification of OEC transplants	5052
the irrefutable identification	5052
OEC transplants	5086
spinal cord injury studies	5105
the mechanisms	5142
OECs	5166
axon regeneration and functional recovery	5186
axon regeneration	5186
functional recovery	5208
acutely transplanted OECs	5266
the glial scar	5306
inhibitory environment	5337
a complete spinal cord transection	5366
we	5402
green fluorescent protein	5419
GFP	5446
control fibroblasts -LRB- FBs -RRB-	5459
control fibroblasts	5459
FBs	5480
OECs derived from GFP-transgenic rats -LRB- Perry et al. , 1999 -RRB-	5489
OECs	5489
GFP-transgenic rats -LRB- Perry et al. , 1999 -RRB-	5507
GFP-transgenic rats	5507
Perry	5528
et al. , 1999	5534
et al.	5534
1999	5542
the survival and engraftment	5559
we	5589
the volume of GFP-positive cells	5603
the volume	5603
GFP-positive cells	5617
the lesion core between 1 and 8 weeks postinjury	5639
the lesion core	5639
between 1 and 8 weeks	5655
OECs	5703
FBs	5736
we	5747
the presence of OECs	5764
the presence	5764
OECs	5780
neurons	5795
a permissive environment	5816
axons postinjury	5845
We	5863
neurons and axons	5877
the lesion core and fewer inhibitory molecules in OEC	5898
the lesion core	5898
fewer inhibitory molecules in OEC	5918
fewer inhibitory molecules	5918
OEC	5948
FB-transplanted spinal cords	5958
FBs and OECs	6009
their modification of the lesion site	6034
their modification	6034
the lesion site	6056
we	6073
astroglial scar formation	6085
the density of activated immune cells and their infiltration	6126
the density	6126
activated immune cells and their infiltration	6141
activated immune cells	6141
their infiltration	6168
the spinal cord stumps	6192
a second part of the study	6219
a second part	6219
the study	6236
we	6247
the pharmacological immunosuppressant , cyclosporine-A -LRB- CSA -RRB- ,	6264
the pharmacological immunosuppressant	6264
cyclosporine-A -LRB- CSA -RRB-	6303
cyclosporine-A	6303
CSA	6319
graft survival	6339
the beneficial effects of OECs	6366
the beneficial effects	6366
OECs	6392
CSA treatment	6398
both FB and OEC survival	6421
FB	6426
OEC survival	6433
OECs	6466
growth permissive cells	6492
the inhibitory environment	6530
secondary tissue damage	6565
axon regeneration	6602
Materials and Methods Animals .	6622
Materials and Methods Animals	6622
Materials	6622
Methods Animals	6636
All animal experimental procedures	6653
All animal	6653
experimental procedures	6664
the Chancellor ` Äôs Animal Research Committee at UCLA	6705
the Chancellor ` Äôs Animal Research Committee	6705
UCLA	6753
accordance	6775
the National Institutes of Health guidelines	6791
the National Institutes	6791
Health guidelines	6818
Animals	6837
standard conditions	6863
ad libitum access to food	6888
ad libitum access	6888
food	6909
a breeding colony	6938
GFP-expressing Sprague - Dawley rats -LRB- Perry et al. , 1999 -RRB-	6959
GFP-expressing Sprague	6959
Dawley rats	6983
Perry	6996
et al. , 1999	7002
et al.	7002
1999	7010
Homozygous and heterozygous rats	7017
PCR -LRB- Perry et al. , 1999 -RRB-	7084
PCR	7084
Perry	7089
et al. , 1999	7095
et al.	7095
1999	7103
rats 8 ` Äì10 weeks old were used to obtain GFP-labeled FBs and OECs	7113
rats	7113
8 ` Äì10 weeks old	7118
8 ` Äì10 weeks	7118
GFP-labeled FBs and OECs	7155
All cells transplanted into rats	7181
All cells	7181
rats	7209
FB or OEC	7259
the paper	7280
Wild-type postnatal day 8 rat pups	7291
cortical neurite outgrowth experiments	7339
An overdose of ketaminexylazine	7379
An overdose	7379
ketaminexylazine	7394
euthanasia	7424
the extraction	7442
the olfactory bulbs , cerebral hemispheres , or abdominal skin biopsies	7460
the olfactory bulbs	7460
cerebral hemispheres	7481
abdominal skin biopsies	7506
Sixty-one female Sprague-Dawley rats	7531
Charles River Laboratories	7569
10 ` Äì12 weeks of age	7598
10 ` Äì12 weeks	7598
age	7615
cell transplants	7629
a complete low-thoracic spinal cord transection	7661
1 , 2 , 4 , or 8 weeks postinjury -LRB- Table 1 -RRB-	7733
1	7733
2	7736
4	7739
8 weeks postinjury -LRB- Table 1 -RRB-	7745
8 weeks	7745
postinjury -LRB- Table 1 -RRB-	7753
postinjury	7753
Table 1	7765
Olfactory bulb-derived OEC cultures .	7775
Olfactory bulb-derived OEC	7775
cultures	7802
Methods to prepare all OEC primary and immunopurified cultures	7812
all OEC	7831
primary and immunopurified cultures	7839
those of Ramo ¬ ¥ n - Cueto et al. -LRB- 2000 -RRB-	7891
those	7891
Ramo ¬ ¥ n - Cueto et al. -LRB- 2000 -RRB-	7900
Ramo ¬ ¥ n	7900
Ramo	7900
¥ n	7905
Cueto et al. -LRB- 2000 -RRB-	7909
Cueto	7909
et al. -LRB- 2000 -RRB-	7915
et al.	7915
2000	7923
those recently reported -LRB- Khankan et al. , 2015 -RRB-	7946
those recently reported	7946
Khankan	7971
et al. , 2015	7979
et al.	7979
2015	7987
OEC dissection from the first two layers of the olfactory bulb	8000
OEC dissection	8000
the first two layers	8020
the olfactory bulb	8044
meninges and blood vessels	8064
fibroblast contamination	8114
Cells	8140
0.1 % trypsin -LRB- Invitrogen -RRB-	8166
0.1 % trypsin	8166
Invitrogen	8180
a mixture	8211
1:1 Dulbecco ` Äôs	8224
Eagle	8250
` Äôs/Ham ` Äôs F12 medium -LRB- D/F medium ; Invitrogen -RRB-	8255
` Äôs/Ham ` Äôs F12 medium	8255
` Äôs/Ham ` Äôs	8255
F12 medium	8268
D/F medium ; Invitrogen	8280
D/F medium	8280
Invitrogen	8292
10 % fetal bovine serum -LRB- FBS ; Hyclone -RRB-	8322
10 % fetal bovine serum	8322
FBS ; Hyclone	8346
FBS	8346
Hyclone	8351
1 % penicillin streptomycin -LRB- P/S ; Invitrogen ; D/F-FBS -RRB-	8364
1 % penicillin streptomycin	8364
P/S	8392
Invitrogen ; D/F-FBS	8397
Invitrogen	8397
D/F-FBS	8409
Medium	8419
every 2 d.	8438
OECs	8461
5 d	8495
p75-nerve growth factor receptor	8529
anti-p75-NGFR , 1:5 ; clone 192 ; Chandler et al. , 1984	8563
anti-p75-NGFR	8563
1:5 ; clone 192 ; Chandler et al.	8578
1:5 ; clone 192	8578
1:5	8578
clone 192	8583
Chandler et al.	8594
Chandler	8594
et al.	8603
1984	8611
OECs	8627
an additional 7 d	8661
D/F-FBS medium	8692
pituitary extract	8725
20 ¬ µg/ml ; Invitrogen	8744
20 ¬ µg/ml	8744
Invitrogen	8755
forskolin	8771
2 ¬ µM ; Sigma-Aldrich	8782
2 ¬ µM	8782
Sigma-Aldrich	8789
Mitogens	8805
cells 1 ` Äì2 d	8834
cells 1	8834
Äì2 d	8842
transplantation or use	8855
neurite outgrowth experiments	8881
Samples of OEC preparations	8912
Samples	8912
OEC preparations	8923
antibodies	8958
p75-NGFR -LRB- 1:5 ; clone 192 -RRB-	8977
p75-NGFR	8977
1:5 ; clone 192	8987
1:5	8987
clone 192	8992
S100 -LRB- 1:1000 ; Dako -RRB-	9004
S100	9004
1:1000 ; Dako	9010
1:1000	9010
Dako	9018
Sox10 -LRB- 1:100 ; R&D Systems -RRB-	9028
Sox10	9028
1:100 ; R&D Systems	9035
1:100	9035
R&D Systems	9042
Fibroblast cell cultures .	9056
Fibroblast	9056
cell cultures	9067
Skin biopsies from the abdominal wall	9082
Skin biopsies	9082
the abdominal wall	9101
fibroblast cultures	9142
Takashima	9178
2001	9189
The dermis	9196
the epidermis and hypodermis	9239
Dermal tissue	9269
0.3 %	9300
10 min at 37 ¬ ∞ C	9310
10 min	9310
37 ¬ ∞ C	9320
D/F-FBS medium	9343
Cells	9359
365µg	9385
5 min	9395
the pellet	9408
12.5 mg/ml collagenase -LRB- Invitrogen -RRB- for 1 h at 37 ¬ ∞ C	9452
12.5 mg/ml collagenase -LRB- Invitrogen -RRB-	9452
12.5 mg/ml collagenase	9452
Invitrogen	9476
1 h at 37 ¬ ∞ C	9492
1 h	9492
37 ¬ ∞ C	9499
The collagenase-cell mixture	9506
a cell strainer	9554
D/F-FBS supplemented with Primocin -LRB- 0.1 mg/ml ; InvivoGen -RRB-	9608
D/F-FBS	9608
Primocin -LRB- 0.1 mg/ml ; InvivoGen -RRB-	9634
Primocin	9634
0.1 mg/ml ; InvivoGen	9644
0.1 mg/ml	9644
InvivoGen	9655
Primary FBs	9667
culture flasks	9694
37 ¬ ∞ C	9724
5 % CO2	9735
the medium	9747
every 2 d. FBs	9770
one to two times	9799
cell transplantation -LRB- 12 ` Äì14 d in vitro -RRB-	9823
cell transplantation	9823
12 ` Äì14 d in vitro	9845
12 ` Äì14 d	9845
12	9845
Äì14 d	9848
vitro	9858
Cortical neurite outgrowth assay .	9866
Cortical neurite	9866
outgrowth assay	9883
neurite	9913
outgrowth experiments	9921
wild-type or GFP-labeled OECs	9944
a concentration	9995
32,000 ` Äì35 ,000 cells	10014
4-well glass slides	10041
poly-L-lysine -LRB- PLL ; 0.05 mg/ml ; Sigma-Aldrich -RRB- 5 d	10077
poly-L-lysine -LRB- PLL ; 0.05 mg/ml ; Sigma-Aldrich -RRB-	10077
poly-L-lysine	10077
PLL	10092
0.05 mg/ml ; Sigma-Aldrich	10097
0.05 mg/ml	10097
Sigma-Aldrich	10109
immunopurification	10134
48 h	10160
cortical neurons	10166
the center of each	10215
the center	10215
each	10229
Cortical neurons	10240
postnatal day 8 rat cerebral cortices	10276
postnatal day	10276
8 rat cerebral cortices	10290
removal of the leptomeninges	10321
removal	10321
the leptomeninges	10332
cerebral cortices	10351
Hibernate	10387
A medium -LRB- BrainBits -RRB-	10398
A medium	10398
BrainBits	10408
P/S	10424
L-glutamine -LRB- L-glu ; Invitrogen -RRB-	10429
L-glutamine	10429
L-glu ; Invitrogen	10442
L-glu	10442
Invitrogen	10449
B27 supplement -LRB- Invitrogen -RRB-	10466
B27 supplement	10466
Invitrogen	10482
Cortices	10495
warm papain -LRB- 2 mg/ml ; Worthington -RRB-	10535
warm papain	10535
2 mg/ml ; Worthington	10548
2 mg/ml	10548
Worthington	10557
Hibernate-A medium with P/S and L-glu	10573
Hibernate-A medium	10573
P/S and L-glu	10597
Neurons	10612
an OptiPrep step gradient -LRB- Axis - Shield -RRB-	10639
an OptiPrep step gradient	10639
Axis - Shield	10666
Axis	10666
Shield	10672
Neurobasal medium -LRB- Invitrogen -RRB-	10696
Neurobasal medium	10696
Invitrogen	10715
they	10747
the positive control	10766
pre-coated laminin PLL -LRB- Laminin 10µg/ml ; Invitrogen -RRB-	10788
pre-coated laminin PLL	10788
Laminin 10µg/ml ; Invitrogen	10814
Laminin 10µg/ml	10814
Invitrogen	10831
the neutral control	10844
PLL only -LRB- 0.05 mg/ml -RRB-	10865
PLL only	10865
0.05 mg/ml	10875
either wild-type or transgenic OECs	10891
PLL wells	10929
a concentration of 100,000 cells per well	10942
a concentration	10942
100,000 cells per well	10961
100,000 cells	10961
the cortical neurons	10999
cultures	11021
an additional 24 h. Cultures	11050
4 % paraformaldehyde for 15 min , washed with buffer	11093
4 % paraformaldehyde	11093
15 min	11117
buffer	11137
neurons	11149
anti- -3-tubulin -LRB- 1:1500 ; Covance -RRB-	11178
anti- -3-tubulin	11178
1:1500 ; Covance	11196
1:1500	11196
Covance	11204
Three independent culture experiments	11214
two wells per experiment per variable	11272
two wells	11272
experiment per variable	11286
experiment	11286
variable	11301
Approximately 10 randomly selected 0.1296 mm2 fields	11325
Approximately 10 randomly	11325
Approximately 10	11325
0.1296 mm2 fields	11360
a Zeiss LSM	11407
510 confocal microscope for neurite outgrowth analysis	11419
510 confocal microscope	11419
neurite outgrowth analysis	11447
Neuronal cell bodies and all neurites	11475
Neuronal cell bodies	11475
all neurites	11500
Neurolucida software -LRB- v10 .31 , MicroBrightField -RRB-	11531
Neurolucida software	11531
v10 .31	11553
MicroBrightField	11561
individual neurite lengths and cell body details	11588
Microsoft Excel using Neurolucida Explorer 10.31	11654
Microsoft Excel	11654
Neurolucida Explorer 10.31	11676
Surgical procedures : spinal cord injury and cell transplantation .	11704
Surgical procedures	11704
spinal cord injury and cell transplantation	11725
All surgeries	11770
aseptic conditions with the rats deeply anesthetized	11805
aseptic conditions	11805
the rats deeply anesthetized	11829
the rats	11829
isoflurane gas administered via facemask	11863
isoflurane gas	11863
facemask	11895
A skin incision	11905
vertebral levels T6	11933
L1	11956
the paravertebral muscles	11960
partial laminectomies at T8 and T9	12006
partial laminectomies	12006
T8 and T9	12031
The dorsal dura	12057
both ends	12122
the spinal cord	12142
most of the lateral and ventral dura	12177
most	12177
the lateral and ventral dura	12185
The spinal cord	12222
spinal level T9 ` ÄìT10	12272
spinal level T9	12272
ÄìT10	12288
micro-scissors	12299
Two surgeons verified that the transection was complete.Atotal of 16 spinal rats	12315
Two surgeons	12315
the transection	12342
16 spinal rats	12381
CSA beginning 3 d	12423
CSA	12423
3 d	12437
the spinal cord transection and transplantation surgery	12448
the end of the study -LRB- Table 1 -RRB-	12524
the end	12524
the study -LRB- Table 1 -RRB-	12535
the study	12535
Table 1	12546
FBs and OECs	12556
a total of 12 ` Äì14 d	12590
a total	12590
12 ` Äì14 d	12601
12	12601
Äì14 d	12604
Cells were rinsed with HBSS without Ca2 +	12621
Cells	12621
HBSS	12644
Ca2	12657
+	12660
Mg2	12662
0.25 % trypsin-EDTA	12688
a medium rinse and centrifugation	12718
a medium rinse	12718
centrifugation	12737
cells	12753
a concentration of 100,000 cells per microliter	12779
a concentration	12779
100,000 cells per microliter	12798
100,000 cells	12798
microliter	12816
serumfree DMEM	12830
A fresh cell preparation	12846
each FB and OEC transplantation	12884
FBs -LRB- 29 rats -RRB- or OECs -LRB- 32 rats -RRB-	12917
FBs -LRB- 29 rats -RRB-	12917
FBs	12917
29 rats	12922
OECs -LRB- 32 rats -RRB-	12934
OECs	12934
32 rats	12940
the spinal cord 1 mm rostral and caudal	12985
the spinal cord 1 mm rostral	12985
caudal	13018
the lesion	13028
the spinal cord transection	13057
Approximately 50,000 cells	13086
four midline injection sites	13136
each spinal cord stump for a total of 200,000 cells per stump	13172
each spinal cord stump	13172
a total of 200,000 cells per stump	13199
a total	13199
200,000 cells per stump	13210
200,000 cells	13210
stump	13228
Rats	13235
an incubator	13255
Spinal rats	13321
manual bladder expression	13342
three times daily	13368
2 weeks and then twice daily	13390
2 weeks	13390
then twice daily	13402
12 h intervals	13433
All animals	13449
weight loss and dehydration	13486
Urine samples	13515
weekly	13541
Multistix	13554
10 SG reagent strips -LRB- Siemens -RRB-	13564
10 SG reagent strips	13564
Siemens	13586
Surgeons and investigators	13596
Surgeons	13596
investigators	13609
treatment group	13639
the time of transplantation	13660
the time	13660
transplantation	13672
the remainder of the study	13699
the remainder	13699
the study	13716
Tissue preparation .	13727
Tissue	13727
preparation	13734
Rats	13747
4 % paraformaldehyde	13803
2 h at 4 ¬	13841
2 h	13841
4	13848
C.	13851
Spinal cords	13854
30 % sucrose	13910
OCT compound -LRB- Tissue-Tek -RRB-	13939
OCT compound	13939
Tissue-Tek	13953
Spinal cords , including the injury site ,	13966
Spinal cords	13966
the injury site	13990
a thickness of 25 ¬ µm	14040
a thickness	14040
25 ¬ µm	14055
tissue sections	14062
series	14094
16 slides	14106
4 ¬ ∞ C in Millonigs buffer	14136
4 ¬ ∞ C	14136
Millonigs buffer	14144
azide	14166
Immunohistochemical procedures	14173
One slide containing every 16th section	14205
One slide	14205
every 16th section	14226
primary antibodies against GFP -LRB- 1:1000 ; Aves Laboratories -RRB-	14264
primary antibodies	14264
GFP -LRB- 1:1000 ; Aves Laboratories -RRB-	14291
GFP	14291
1:1000 ; Aves Laboratories	14296
1:1000	14296
Aves Laboratories	14304
Glial Fibrillary Acidic Protein	14324
GFAP ; monoclonal 1:1000 ; BD Biosciences ; polyclonal 1:10 K ; Dako	14357
GFAP	14357
monoclonal 1:1000 ; BD Biosciences ; polyclonal 1:10 K ; Dako	14363
monoclonal 1:1000	14363
BD Biosciences ; polyclonal 1:10 K ; Dako	14382
1:10 K	14409
one additional marker	14427
neurons -LRB- NeuN , 1:1000 ; Millipore -RRB-	14461
neurons	14461
NeuN , 1:1000 ; Millipore	14470
NeuN	14470
1:1000 ; Millipore	14476
1:1000	14476
Millipore	14484
serotonergic axons -LRB- 5-HT , 1:5000 ; ImmunoStar -RRB-	14496
serotonergic axons	14496
5-HT , 1:5000 ; ImmunoStar	14516
5-HT	14516
1:5000 ; ImmunoStar	14522
1:5000	14522
ImmunoStar	14530
neurofilament -LRB- NF-H , 1:1000 ; Millipore -RRB-	14543
neurofilament	14543
NF-H , 1:1000 ; Millipore	14558
NF-H	14558
1:1000 ; Millipore	14564
1:1000	14564
Millipore	14572
immune cells -LRB- Iba-1 , 1:5000 ; Wako Chemicals -RRB-	14584
immune cells	14584
Iba-1 , 1:5000 ; Wako Chemicals	14598
Iba-1	14598
1:5000 ; Wako Chemicals	14605
1:5000	14605
Wako Chemicals	14613
native chondroitin sulfate proteoglycans	14630
CS-56 , 1:200 ; Sigma-Aldrich	14672
CS-56	14672
1:200 ; Sigma-Aldrich	14679
1:200	14679
Sigma-Aldrich	14686
water channel aquaporin 4 -LRB- AQP4 , 1:1000 ; Sigma-Aldrich -RRB-	14702
water channel aquaporin	14702
4 -LRB- AQP4 , 1:1000 ; Sigma-Aldrich -RRB-	14726
4	14726
AQP4 , 1:1000 ; Sigma-Aldrich	14729
AQP4	14729
1:1000 ; Sigma-Aldrich	14735
1:1000	14735
Sigma-Aldrich	14743
fibronectin	14762
FN ; monoclonal 1:200 ; BD Biosciences ; polyclonal 1:1000 ; Dako	14775
FN	14775
monoclonal 1:200 ; BD Biosciences ; polyclonal 1:1000 ; Dako	14779
monoclonal 1:200	14779
BD Biosciences ; polyclonal 1:1000 ; Dako	14797
1:1000	14824
Sections	14839
species	14881
appropriate serum	14889
a presoak -LRB- donkey , Jackson ImmunoResearch ;	14910
a presoak	14910
donkey , Jackson ImmunoResearch	14921
donkey	14921
Jackson ImmunoResearch	14929
goat serum , Vector Laboratories	14956
goat serum	14956
Vector Laboratories	14968
incubation with primary antibodies overnight	14996
incubation	14996
primary antibodies overnight	15012
primary antibodies	15012
immunostaining	15055
species appropriate AlexaFluor 488 , 555 , 594 , or 647	15071
species	15071
AlexaFluor 488 , 555 , 594 , or 647	15091
AlexaFluor 488	15091
555 , 594 , or 647	15107
1:100	15125
` Äì500 ; Jackson ImmunoResearch	15131
` Äì500	15131
Jackson ImmunoResearch	15139
Nuclei	15173
Hoechst	15198
Sigma-Aldrich	15211
5 min and sections	15230
5 min	15230
sections	15240
Fluorogel -LRB- Electron Microscopy Sciences -RRB-	15272
Fluorogel	15272
Electron Microscopy Sciences	15283
Electron	15283
Microscopy Sciences	15292
Oil red and GFAP bright-field staining .	15314
Oil red and GFAP	15314
bright-field staining	15331
Slide-mounted sections	15354
ddH2O for 5 min	15394
ddH2O	15394
5 min	15404
70 % ethanol for 5 min	15426
70 % ethanol	15426
5 min	15442
Sections	15449
Oil RedOstain	15478
700 mg of Oil Red powder	15493
700 mg	15493
Oil Red powder	15503
100 ml of 70 % ethanol , filtered twice , Sigma-Aldrich	15531
100 ml	15531
70 % ethanol , filtered twice , Sigma-Aldrich	15541
70 % ethanol	15541
Sigma-Aldrich	15570
30 min	15589
ethanol for 1 min and ddH2Ofor 5 min -LRB- Ma et al. , 2002 -RRB-	15619
ethanol for 1 min	15619
ethanol	15619
1 min	15631
ddH2Ofor 5 min -LRB- Ma et al. , 2002 -RRB-	15641
ddH2Ofor	15641
5 min -LRB- Ma et al. , 2002 -RRB-	15650
Ma	15657
et al. , 2002	15660
et al.	15660
2002	15668
Sections	15675
0.1 M Tris	15701
1.4 % NaCl and 0.1 % BSA followed by 15 min in 0.1 % Triton detergent buffer	15723
1.4 % NaCl	15723
0.1 % BSA followed by 15 min in 0.1 % Triton detergent buffer	15737
0.1 % BSA	15737
15 min in 0.1 % Triton detergent buffer	15758
15 min	15758
0.1 % Triton detergent buffer	15768
0.1 %	15768
Triton detergent buffer	15773
Sections	15798
5 % donkey serum	15825
0.1 % Triton before incubation	15852
0.1 % Triton	15852
incubation	15871
anti-GFAP overnight	15887
Sections	15908
Tris buffer	15935
a	15952
rabbit secondary antibody , amplified by incubation with avidin-biotin complex ,	15967
rabbit secondary antibody	15967
incubation	16007
avidin-biotin complex	16023
diaminobenzidine -LRB- Dojindo Laboratories -RRB-	16067
diaminobenzidine	16067
Dojindo Laboratories	16085
Lesion site analyses .	16108
Lesion	16108
site analyses	16115
All anatomical analyses	16130
cell transplant type	16178
Photomicrographic montages of spinal cord sections	16200
Photomicrographic montages	16200
spinal cord sections	16230
an Olympus AX70 microscope	16267
Zen 2012 image capture software -LRB- Carl Zeiss -RRB-	16298
Zen 2012 image capture	16298
software -LRB- Carl Zeiss -RRB-	16321
software	16321
Carl Zeiss	16331
the panorama module	16348
Confocal images	16369
a Zeiss LSM 510 or 800 microscope and 25 or 63 oil objective	16404
a Zeiss LSM 510 or 800 microscope	16404
a Zeiss LSM	16404
510 or 800 microscope	16416
25 or 63 oil objective	16442
Analyses and 3D visualization	16468
Analyses	16468
3D visualization	16481
the Neurolucida and Neurolucida Explorer software	16518
v10 , MicroBrightField	16569
v10	16569
MicroBrightField	16574
the survival and migration of transplanted FBs and OECs	16606
the survival and migration	16606
transplanted FBs and OECs	16636
we	16663
the GFP-positive area	16673
the lesion core and stumps	16698
the lesion core	16698
stumps	16718
every eighth section	16728
The percentage of GFP-positive cells in the lesion core	16750
The percentage	16750
GFP-positive cells in the lesion core	16768
GFP-positive cells	16768
the lesion core	16790
the volume of GFP	16821
the volume	16821
GFP	16835
the lesion core	16842
the total volume of GFP	16869
the total volume	16869
GFP	16889
the lesion core plus stumps	16900
the lesion core	16900
stumps	16921
FB and OEC filling of the lesion core	16942
FB and OEC filling	16942
the lesion core	16964
the areas of GFP-labeled cells	16981
the areas	16981
GFP-labeled cells	16994
fibronectin-positive extracellular matrix in the lesion core	17016
fibronectin-positive extracellular matrix	17016
the lesion core	17061
every 16th section of the spinal cord	17094
every 16th section	17094
the spinal cord	17116
volumes	17145
Kubasak	17169
et al. -LRB- 2008 -RRB-	17177
et al.	17177
2008	17185
We	17192
the percentage of GFP-positive cells that fill the GFAPnegative lesion volume	17202
the percentage	17202
GFP-positive cells	17220
the GFAPnegative lesion volume	17249
the extent of neuronal preservation	17294
the extent	17294
neuronal preservation	17308
the length of the nonneuronal tissue	17331
the length	17331
the nonneuronal tissue	17345
Takeoka et al. -LRB- 2011 -RRB-	17389
Takeoka et al.	17389
Takeoka	17389
et al.	17397
2011	17405
every eighth section	17416
the distance	17438
the neuron closest to the rostral and caudal GFAP-positive stumps	17459
the neuron	17459
the rostral and caudal GFAP-positive stumps	17481
the rostral	17481
caudal GFAP-positive stumps	17497
the total distance of the non-neuronal tissue and lesion core	17549
the total distance	17549
the non-neuronal tissue and lesion core	17571
the preservation of axons postinjury	17625
the preservation	17625
axons postinjury	17645
we	17663
serotonergic axons	17675
the rostral stump associated with the GFAP border in every 16th section	17705
the rostral stump	17705
the GFAP border in every 16th section	17739
the GFAP border	17739
every 16th section	17758
Axon sparing	17778
Axon	17778
the number	17820
5-HT-positive axons that crossed the GFAP-positive border into the lesion core	17834
5-HT-positive axons	17834
the GFAP-positive border	17867
the lesion core	17897
the total area	17918
5-HT-labeled axons within the GFAP-negative lesion core	17936
5-HT-labeled axons	17936
the GFAP-negative lesion core	17962
the distance	18001
the rostral border to the most caudal 5-HT-labeled axon in the lesion core	18019
the rostral border	18019
the most caudal 5-HT-labeled axon in the lesion core	18041
the most caudal 5-HT-labeled axon	18041
the lesion core	18078
Axons that did not extend beyond the GFAP-positive border	18095
Axons	18095
the GFAP-positive border	18128
zero	18168
negative lengths	18191
changes	18222
immune cell activation , astrocyte reactivity , and CSPG deposition	18233
immune cell activation	18233
astrocyte reactivity	18257
CSPG deposition	18283
luminance measurements	18305
Iba-1 , GFAP , and CS-56 immunoreactivity	18332
images of every 16th section	18406
images	18406
every 16th section	18416
Images	18436
identical exposure conditions	18463
the mean pixel luminance	18514
individual channels using the Zen 2012 annotations/measurements feature	18544
individual channels	18544
the Zen 2012 annotations/measurements feature	18570
the Iba-1 analysis	18621
five zones	18641
rectangles -LRB- 500,000 m2 -RRB- on the image	18667
rectangles -LRB- 500,000 m2 -RRB-	18667
rectangles	18667
500,000 m2	18679
the image	18695
rostral stump , rostral border , lesion core , caudal border , or caudal stump	18729
rostral stump	18729
rostral border	18744
lesion core	18760
caudal border	18773
caudal stump	18791
Luminance measurements for the CS-56 analysis	18805
Luminance measurements	18805
the CS-56 analysis	18832
eight zones	18867
squares -LRB- 6500 m2 -RRB- within the GFAP-positive rostral	18889
squares -LRB- 6500 m2 -RRB-	18889
squares	18889
6500 m2	18899
the GFAP-positive rostral	18916
caudal borders and GFAPnegative lesion core	18946
caudal borders	18946
GFAPnegative lesion core	18965
Additional luminance measurements for CS-56	18991
Additional luminance measurements	18991
CS-56	19029
eight zones with GFP-FBs , GFP-OECs , and adjacent zones	19051
eight zones	19051
GFP-FBs , GFP-OECs , and adjacent zones	19068
GFP-FBs	19068
GFP-OECs	19077
adjacent zones	19091
GFP cells	19114
Rectangles	19125
the GFAP-positive border	19154
cysts	19183
a control	19206
the GFAP luminance	19217
the same Iba-1 and CS-56 zones	19257
the same Iba-1	19257
CS-56 zones	19276
Mean luminance intensity measurements	19289
Iba-1 , GFAP , and CS-56 immunoreactivity	19336
background auto-fluorescence of each sec - tion	19395
background auto-fluorescence	19395
each sec - tion	19427
Results	19443
a fold-change from background levels and luminance values	19468
a fold-change	19468
background levels and luminance values	19487
zones for each animal	19547
zones	19547
each animal	19557
Myelin phagocytosis assay .	19570
Myelin	19570
phagocytosis assay	19577
p75-NGFR-positive OECs	19606
a concentration of 25,000 cells	19644
a concentration	19644
25,000 cells	19663
PLL-coated 15-mm-round coverslips	19681
overnight	19734
OECs	19745
Cell - Tracker Green CMFDA -LRB- 7 ¬ µM ; Invitrogen -RRB-	19771
Cell	19771
Tracker Green CMFDA	19777
7 ¬ µM ; Invitrogen	19798
7 ¬ µM	19798
Invitrogen	19805
24 h. Myelin	19844
Colman et al. , 1982 ; Zheng et al. , 2003 ; Runyan and Phelps , 2009	19895
Colman	19895
et al. , 1982 ; Zheng et al. , 2003 ; Runyan and Phelps , 2009	19902
et al. , 1982	19902
et al.	19902
1982	19910
Zheng et al. , 2003	19916
Zheng	19916
et al. , 2003	19922
et al.	19922
2003	19930
Runyan and Phelps , 2009	19936
Runyan and Phelps	19936
2009	19955
Myelin	19962
D/F-FBS media	19984
OEC-coated coverslips	20008
a final concentration of 0.1 mg/ml	20033
a final concentration	20033
0.1 mg/ml	20058
37 ¬ ∞ C	20093
1 h. Coverslips	20103
media	20136
excess	20152
4 % paraformaldehyde for 30 min	20178
4 % paraformaldehyde	20178
30 min	20202
three times	20221
PBS	20238
immunocytochemical staining	20249
OECs	20278
5 %	20308
Triton X-100 solution -LRB- Sigma-Aldrich -RRB- ,	20311
Triton X-100 solution	20311
Sigma-Aldrich	20334
normal donkey serum	20363
overnight with anti-myelin basic protein -LRB- MBP ; 1:250 ; Millipore -RRB-	20398
overnight	20398
anti-myelin basic protein -LRB- MBP ; 1:250 ; Millipore -RRB-	20413
anti-myelin basic protein	20413
MBP	20440
1:250 ; Millipore	20445
1:250	20445
Millipore	20452
immunostaining	20477
cells	20493
donkey anti-chick	20519
IgY-Rhodamine -LRB- 1:500 , Jackson ImmunoResearch -RRB- for 1 h. Coverslips	20538
IgY-Rhodamine -LRB- 1:500 , Jackson ImmunoResearch -RRB-	20538
IgY-Rhodamine	20538
1:500	20553
Jackson ImmunoResearch	20560
1 h. Coverslips	20588
glass slides	20622
Fluorogel	20640
Images	20651
a Zeiss LSM	20678
510 confocal microscope and 63 objective	20690
510 confocal microscope	20690
63 objective	20718
Statistical analyses	20733
Measurements from each analysis	20755
Measurements	20755
each analysis	20773
a mean for each animal	20811
a mean	20811
each animal	20822
The mean values for each rat	20835
The mean values	20835
each rat	20855
a group	20883
each time point	20900
mean ¬ ± SEM	20932
All statistical comparisons	20945
JMP Software -LRB- v10 .0.0 for Microsoft Windows , SAS Institute -RRB- orR	20993
JMP Software -LRB- v10 .0.0 for Microsoft Windows , SAS Institute -RRB-	20993
JMP Software	20993
v10 .0.0 for Microsoft Windows , SAS Institute	21007
v10 .0.0	21007
Microsoft Windows , SAS Institute	21019
Microsoft Windows	21019
SAS Institute	21038
3.2.2	21057
RCore Team , 2015	21063
RCore Team	21063
2015	21075
A two-way ANOVA	21082
the pooled effects of time and cell transplant groups	21123
the pooled effects	21123
time and cell transplant groups	21145
group	21189
time pointsMANOVAfollowed by a two-wayANOVAwas used	21208
time	21208
a two-wayANOVAwas used	21237
a two-wayANOVAwas	21237
Post hoc tests -LRB- Student ` Äôs t tests -RRB-	21261
Post hoc tests	21261
Post	21261
hoc	21266
tests	21270
Student ` Äôs t tests	21277
Student ` Äôs	21277
Student	21277
Äôs	21285
t tests	21289
interactions	21318
the case where the sample size was small	21349
the case	21349
the sample size	21364
95 % confidence intervals	21391
Monte Carlo	21434
simulation and significance	21446
nonparametric , Bootstrap approximation of a two-way repeatedmeasures ANOVA	21488
Bootstrap approximation of a two-way repeatedmeasures	21503
Bootstrap approximation	21503
a two-way repeatedmeasures	21530
Statistical significance	21564
p <	21608
p	21608
<	21610
0.05 , ** p < 0.01 , and *** p <	21611
0.05 , ** p < 0.01 ,	21611
0.05	21611
p <	21619
p	21619
<	21621
0.01	21622
*** p <	21632
*** p	21632
0.001	21638
Results Figure 1 .	21646
Results	21646
Figure 1	21654
Survival and migration of transplanted cells .	21664
Survival and migration	21664
transplanted cells	21690
A ` ÄìF , GFP-labeled FBs -LRB- A , C , E -RRB- or OECs -LRB- B , D , F -RRB-	21710
A ` ÄìF	21710
GFP-labeled FBs -LRB- A , C , E -RRB- or OECs -LRB- B , D , F -RRB-	21717
GFP-labeled FBs -LRB- A , C , E -RRB-	21717
GFP-labeled FBs	21717
A , C , E	21734
OECs -LRB- B , D , F -RRB-	21746
OECs	21746
B , D , F	21752
the lesion core -LRB- asterisks -RRB-	21782
the lesion core	21782
asterisks	21799
GFAP-positive -LRB- cyan -RRB- rostral and caudal stumps between 1 and 4 weeks	21817
GFAP-positive -LRB- cyan -RRB- rostral	21817
caudal stumps between 1 and 4 weeks	21850
caudal stumps	21850
between 1 and 4 weeks	21864
spinal cord transection and cell transplantation	21892
Anti-GFP immunolabeling	21942
large numbers	21977
FBs and OECs	22004
the lesion core -LRB- white arrowheads -RRB- and stumps -LRB- white arrows -RRB-	22020
the lesion core	22020
white arrowheads	22037
stumps	22059
white arrows	22067
1 week post-transplant -LRB- A , B -RRB-	22084
1 week	22084
A , B	22108
A	22108
B	22111
2 weeks	22118
neither FBs nor OECs	22127
FBs	22135
OECs	22143
the lesion core	22160
GFP-positive cells	22181
the stumps	22215
white arrows	22233
4 weeks	22251
no FBs	22259
-LRB- E -RRB-	22275
OECs	22288
the lesion core	22308
white arrowhead	22325
stumps	22346
F , white arrow	22354
F	22354
white arrow	22357
Neither FBs nor OECs	22371
FBs	22379
OECs	22387
8 weeks -LRB- data not shown -RRB-	22404
8 weeks	22404
data not shown	22413
data	22413
Confocal images	22436
FBs -LRB- G -RRB-	22467
FBs	22467
G	22472
dense sheets of cells -LRB- yellow arrowheads -RRB-	22478
dense sheets	22478
cells -LRB- yellow arrowheads -RRB-	22494
cells	22494
yellow arrowheads	22501
OECs -LRB- H -RRB-	22529
OECs	22529
H	22535
thin tubular tracks of cells -LRB- yellow arrows -RRB-	22545
thin tubular tracks	22545
cells -LRB- yellow arrows -RRB-	22568
cells	22568
yellow arrows	22575
I	22591
Confocal image	22594
intermingled spindle-shaped OECs -LRB- inset -RRB-	22615
intermingled spindle-shaped OECs	22615
4 weeks	22659
postinjury	22667
a trabecular network	22685
fibronectin-positive -LRB- red -RRB- extracellular matrix	22709
the lesion core	22760
J	22777
more of the lesion core	22804
more	22804
the lesion core	22812
the total GFP volume than FBs at 4 weeks	22840
the total GFP volume	22840
FBs at 4 weeks	22866
FBs	22866
4 weeks	22873
other time points	22914
Circles	22933
individual animals and group	22951
individual animals	22951
group	22974
SEM values	22986
black for FBs	23010
black	23010
FBs	23020
OECs in this and subsequent figures	23038
OECs	23038
this and subsequent figures	23046
this	23046
subsequent figures	23055
All sagittal spinal cord images	23075
rostral to the left and dorsal to the top	23125
rostral	23125
the left and dorsal to the top	23136
the left and dorsal	23136
the top	23159
Scale bars : A ` ÄìF , 1 mm ; G , H , 50 ¬ µm ; I , 200 ¬ µm .	23168
Scale bars	23168
A ` ÄìF , 1 mm	23180
A ` ÄìF	23180
1 mm	23187
G , H , 50 ¬ µm	23193
G	23193
H , 50 ¬ µm	23196
H	23196
50 ¬ µm	23199
I , 200 ¬ µm	23206
I	23206
200 ¬ µm	23209
Figure 2 .	23218
Figure	23218
2	23225
OECs	23228
neuronal degeneration	23240
A , At 2 weeks	23263
2	23269
an OEC-transplanted spinal cord	23288
the astroglial scar border identified with GFAP -LRB- cyan -RRB-	23324
the astroglial scar border identified with GFAP	23324
the astroglial scar border	23324
GFAP	23367
cyan	23373
neurons -LRB- yellow arrows -RRB- marked with NeuN -LRB- red -RRB-	23383
neurons -LRB- yellow arrows -RRB- marked with NeuN	23383
neurons -LRB- yellow arrows -RRB-	23383
neurons	23383
yellow arrows	23392
NeuN	23419
red	23425
No OECs	23431
this section	23455
The distance	23469
neurons	23490
yellow arrows	23499
the nearest astrocyte scar border	23518
c	23553
the total distance between rostral and caudal neurons	23560
the total distance	23560
rostral and caudal neurons	23587
d	23615
measured.B	23623
Confocal image near the rostral scar border	23635
Confocal image	23635
the rostral scar border	23655
neurons	23688
white arrows	23697
OECs	23725
A , c	23825
A	23825
c	23827
andthetotaldistancebetweentheneuronsofthe rostral	23829
caudal stumps -LRB- A , d -RRB-	23883
caudal stumps	23883
A , d	23898
A	23898
d	23901
FB	23920
OEC-treated rats at 1 and 2 weeks postinjury	23929
OEC-treated rats	23929
1 and 2 weeks postinjury	23949
Scale bars : A , 500 ¬ µm ; B , 50 ¬ µm .	23975
Scale bars	23975
A , 500 ¬ µm	23987
A	23987
500 ¬ µm	23990
B , 50 ¬ µm	23997
B	23997
50 ¬ µm	24000
Figure 3 .	24008
Figure	24008
3	24015
OECs	24018
serotonergic axonal dieback	24030
A ` ÄìD	24059
Representative images -LRB- A , C -RRB- and enlargements -LRB- B , D -RRB-	24066
Representative images -LRB- A , C -RRB-	24066
Representative images	24066
A , C	24089
A	24089
C	24092
enlargements -LRB- B , D -RRB-	24099
enlargements	24099
B , D	24113
B	24113
D	24116
serotonergic axons	24124
5-HT , red	24144
5-HT	24144
red	24150
yellow arrowheads	24175
the GFAP-positive rostral	24194
border	24220
the lesion core -LRB- * , yellow arrows -RRB- in FB	24236
the lesion core -LRB- * , yellow arrows -RRB-	24236
the lesion core	24236
* , yellow arrows	24253
*	24253
yellow arrows	24256
FB	24274
A , B	24279
A	24279
B	24282
OEC-transplanted -LRB- C , D -RRB- spinal cords	24289
E , Confocal image	24327
5-HT axons	24356
the astroglial scar border -LRB- white arrowheads -RRB-	24390
the astroglial scar border	24390
white arrowheads	24418
OECs -LRB- white arrows -RRB-	24448
OECs	24448
white arrows	24454
the GFAP-negative lesion core -LRB- inset -RRB-	24485
the GFAP-negative lesion core	24485
inset	24516
F	24524
Groups	24527
OECs	24537
bundles of NF-H-positive axons -LRB- red -RRB- and astrocytes -LRB- cyan -RRB-	24567
bundles	24567
NF-H-positive axons -LRB- red -RRB- and astrocytes -LRB- cyan -RRB-	24578
NF-H-positive axons	24578
red	24599
astrocytes	24608
cyan	24620
scaffolds	24635
OECs and axons	24649
the scar border -LRB- white arrowheads -RRB-	24681
the scar border	24681
white arrowheads	24698
average	24726
more 5-HT-labeled axon bundles	24735
the rostral border in OEC	24772
the rostral border	24772
OEC	24794
FB-treated rats at 1 and 2 weeks postinjury -LRB- G -RRB-	24804
FB-treated rats	24804
1 and 2 weeks postinjury -LRB- G -RRB-	24823
1 and 2 weeks postinjury	24823
G	24849
The distance between the scar border and the most caudally extending 5-HT axon	24853
The distance	24853
the scar border and the most caudally extending 5-HT axon	24874
the scar border	24874
the most caudally extending 5-HT axon	24894
the most	24894
5-HT axon	24922
greater in OEC	24936
greater	24936
OEC	24947
FB-treated rats at 2 weeks -LRB- H -RRB-	24957
FB-treated rats	24957
2 weeks -LRB- H -RRB-	24976
2 weeks	24976
H	24985
Scale bars : A , C , 200 ¬ µm ; B , D ` ÄìF , 50 ¬ µm .	24989
Scale bars	24989
A	25001
C	25004
200 ¬ µm ; B	25007
200 ¬ µm	25007
B	25015
D ` ÄìF	25018
D	25018
ÄìF	25020
50 ¬ µm	25025
Figure 4 .	25033
Figure	25033
4	25040
OECs	25043
inhibitory CSPGs	25055
the lesion core	25075
astrocyte border formation	25106
A , B , The spinal cord injury site and caudal stump border	25134
B	25136
The spinal cord injury site and caudal stump border	25139
astrocytes -LRB- GFAP , cyan -RRB-	25207
astrocytes	25207
GFAP , cyan	25219
GFAP	25219
cyan	25225
CSPGs -LRB- CS-56 , red -RRB-	25232
CSPGs	25232
CS-56	25239
red	25246
FBs -LRB- A , green -RRB-	25256
FBs	25256
A , green	25261
A	25261
green	25264
OECs -LRB- B , green -RRB- at 2 weeks postinjury	25274
OECs -LRB- B , green -RRB-	25274
OECs	25274
B , green	25280
B	25280
green	25283
2 weeks postinjury	25293
FBs -LRB- A , white arrows -RRB-	25313
FBs	25313
A , white arrows	25318
A	25318
white arrows	25321
high levels of CSPG	25348
high levels	25348
CSPG	25363
OECs -LRB- B , yellow arrows -RRB-	25376
OECs	25376
B , yellow arrows	25382
B	25382
yellow arrows	25385
the inverse	25405
Astrocyte processes in OEC-treated spinal cords	25418
Astrocyte processes	25418
OEC-treated spinal cords	25441
CSPG-positive cells -LRB- B , yellow arrowheads -RRB-	25475
CSPG-positive cells	25475
B , yellow arrowheads	25496
B	25496
yellow arrowheads	25499
a function	25519
FB-treated rats -LRB- A , white arrowheads -RRB-	25543
FB-treated rats	25543
A , white arrowheads	25560
A	25560
white arrowheads	25563
Individual channels of the entire image	25582
Individual channels	25582
the entire image	25605
the right	25639
distribution of each antibody	25657
distribution	25657
each antibody	25673
The mean luminance of CSPGs	25694
The mean luminance	25694
CSPGs	25716
the lesion core -LRB- C -RRB- and the rostral	25737
the lesion core -LRB- C -RRB-	25737
the lesion core	25737
C	25754
the rostral	25761
caudal stumps -LRB- D -RRB- of FB -LRB- black -RRB-	25777
caudal stumps -LRB- D -RRB-	25777
caudal stumps	25777
D	25792
FB -LRB- black -RRB-	25798
FB	25798
of OEC -LRB- green -RRB- transplanted spinal cords at 2 , 4 ,	25814
OEC -LRB- green -RRB-	25817
OEC	25817
transplanted spinal cords	25829
2 , 4 ,	25858
2	25858
4	25861
8 weeks postinjury	25868
8 weeks	25868
postinjury	25876
E , F , Astrocyte morphology at the lesion border ,	25888
E	25888
F	25891
Astrocyte morphology at the lesion border	25894
Astrocyte morphology	25894
the lesion border	25918
combined Aquaporin 4	25946
AQP4 , cyan	25968
AQP4	25968
cyan	25974
GFAP -LRB- cyan -RRB- staining ,	25984
GFAP	25984
cyan	25990
staining	25996
FB - -LRB- E -RRB- but not OEC-treated -LRB- F -RRB- spinal cords	26020
FB	26020
-LRB- E -RRB- but not OEC-treated -LRB- F -RRB- spinal cords	26024
-LRB- E -RRB-	26024
not OEC-treated -LRB- F -RRB- spinal cords	26032
F	26049
2 weeks postinjury	26069
Astrocytic processes	26089
a palisading arrangement	26115
OECs -LRB- F , yellow arrowheads -RRB-	26161
OECs	26161
F , yellow arrowheads	26167
F	26167
yellow arrowheads	26170
FBs -LRB- E , white arrowheads -RRB-	26233
FBs	26233
E , white arrowheads	26238
E	26238
white arrowheads	26241
High levels of fibronectin -LRB- red -RRB-	26260
High levels of fibronectin	26260
High levels	26260
fibronectin	26275
red	26288
FBs -LRB- E , individual channels -RRB-	26313
FBs	26313
E , individual channels	26318
E	26318
individual channels	26321
fibronectin-positive cells	26351
F , individual channels	26395
F	26395
individual channels	26398
astrocytes -LRB- yellow arrowheads -RRB-	26422
astrocytes	26422
yellow arrowheads	26434
OEC-treated rats	26456
Scale bars : A , B , E , F , 200 ¬ µm .	26474
Scale bars	26474
A , B , E , F , 200 ¬ µm	26486
A	26486
B	26489
E	26492
F	26495
200 ¬ µm	26498
Figure 5 .	26507
Figure	26507
5	26514
OECs	26517
myelin debris	26529
2 , 4 , and 8 weeks postinjury	26546
2	26546
4	26549
8 weeks postinjury	26556
8 weeks	26556
postinjury	26564
Distribution of Oil Red O-labeled myelin debris -LRB- red puncta -RRB-	26576
Distribution	26576
Oil Red O-labeled myelin debris	26592
red puncta	26625
the lesion core -LRB- * -RRB- and stumps of FB -	26640
the lesion core -LRB- * -RRB-	26640
the lesion core	26640
stumps of FB	26664
stumps	26664
FB	26674
A , C , E	26679
OEC-treated spinal cords -LRB- B , D , F -RRB-	26692
OEC-treated spinal cords	26692
B , D , F	26718
The astroglial scar border	26738
GFAP -LRB- brown -RRB- immunostaining	26780
GFAP	26780
-LRB- brown -RRB- immunostaining	26785
A , B ,	26809
B	26812
2 weeks	26818
postinjury myelin debris -LRB- black arrows -RRB-	26826
postinjury myelin debris	26826
black arrows	26852
the lesion border	26882
the stumps	26909
FB-treated -LRB- A -RRB- rats	26923
A	26935
less	26952
OEC-transplanted -LRB- B -RRB- rats	26970
B	26988
C ` ÄìF , Oil Red O-positive staining	26997
C	26997
ÄìF	26999
Oil Red O-positive staining	27004
the lesion site of FB	27054
the lesion site	27054
FB	27073
C , E	27078
C	27078
E	27081
not OEC-treated -LRB- D , F -RRB- spinal cords at 4 and 8 weeks	27088
not OEC-treated -LRB- D , F -RRB- spinal cords	27088
D , F	27105
D	27105
F	27108
at 4 and 8 weeks	27125
a ` Äìf	27154
Enlarged images	27161
the	27180
areas -LRB- insets -RRB- in A ` ÄìF show more red punctate	27190
areas -LRB- insets -RRB- in A ` ÄìF show	27190
areas -LRB- insets -RRB-	27190
areas	27190
insets	27197
A ` ÄìF show	27208
myelin debris -LRB- arrowheads -RRB-	27237
myelin debris	27237
arrowheads	27252
FB	27267
OEC-treated rats	27276
Scale bars : A ` ÄìF , 1 mm ; a ` Äìf , 100 ¬ µm .	27294
Scale bars	27294
A ` ÄìF , 1 mm	27306
A ` ÄìF	27306
1 mm	27313
a ` Äìf , 100 ¬ µm	27319
a ` Äìf	27319
100 ¬ µm	27326
Figure 6 .	27335
Figure	27335
6	27342
OECs	27345
immune cell activation	27357
the first 2 weeks postinjury	27387
A , Lesion site of an OEC-transplanted spinal cord 2 weeks postinjury	27417
A , Lesion site of an OEC-transplanted spinal cord	27417
Lesion site	27420
an OEC-transplanted	27435
2 weeks	27467
microglia/macrophages	27498
Iba-1 , red	27521
Iba-1	27521
red	27528
astrocytes	27537
GFAP , cyan	27549
GFAP	27549
cyan	27555
OECs	27562
this section	27587
White boxes	27601
the zones in which Iba-1 and GFAP immunofluorescence intensities were measured	27623
the zones	27623
Iba-1 and GFAP immunofluorescence intensities	27642
B ` ÄìE	27703
B	27703
ÄìE	27705
Graphical representation	27710
the mean Iba-1 luminance	27738
the rostral border -LRB- B -RRB-	27766
the rostral border	27766
B	27786
caudal border -LRB- C -RRB-	27790
caudal border	27790
C	27805
rostral stump -LRB- D -RRB-	27809
rostral stump	27809
D	27824
caudal stump -LRB- E -RRB-	27832
caudal stump	27832
E	27846
2 weeks	27853
Iba-1 intensities	27862
greater in FB	27885
greater	27885
FB	27896
OEC-treated spinal cords	27905
Scale bar : A , 500 ¬ µm .	27931
Scale bar	27931
A , 500 ¬ µm	27942
A	27942
500 ¬ µm	27945
Figure 7 .	27954
Figure	27954
7	27961
OECs	27964
immune cell infiltration	27976
the spinal cord stumps	28006
A ` ÄìD	28030
the rostral -LRB- A , B -RRB- and caudal border -LRB- C , D -RRB- zones	28044
the rostral -LRB- A , B -RRB-	28044
the rostral	28044
A , B	28057
A	28057
B	28060
caudal border -LRB- C , D -RRB- zones	28067
astrocytes -LRB- GFAP , cyan -RRB-	28095
astrocytes	28095
GFAP , cyan	28107
GFAP	28107
cyan	28113
activated macrophages / microglia -LRB- Iba-1 , red -RRB- are immunolabeled	28123
activated macrophages	28123
microglia -LRB- Iba-1 , red -RRB-	28146
microglia	28146
Iba-1 , red	28157
Iba-1	28157
red	28164
nuclei	28191
Hoechst	28211
yellow	28220
These images from FB - -LRB- A , C -RRB-	28229
These images	28229
FB	28247
A , C	28252
A	28252
C	28255
OEC-treated -LRB- B , D -RRB- lesion sites	28262
B , D	28275
B	28275
D	28278
2 -LRB- A , B -RRB- and 4 weeks -LRB- C , D -RRB- postinjury	28298
2 -LRB- A , B -RRB-	28298
2	28298
A , B	28301
A	28301
B	28304
4 weeks -LRB- C , D -RRB-	28311
postinjury	28326
Individual channels of the entire image	28338
Individual channels	28338
the entire image	28361
the left	28395
The GFAP scar border -LRB- cyan image -RRB-	28405
The GFAP scar border	28405
cyan image	28427
A ` ÄìD	28459
The distribution	28467
Iba-1-positive immune cells -LRB- red image -RRB-	28487
Iba-1-positive immune cells	28487
red image	28516
the GFAP-positive scar border and the lesion core	28535
the GFAP-positive scar border	28535
the lesion core	28569
the FB -LRB- A , C -RRB- versus OEC -LRB- B , D -RRB- sections	28600
the FB -LRB- A , C -RRB-	28600
the FB	28600
A , C	28608
A	28608
C	28611
OEC -LRB- B , D -RRB- sections	28621
OEC -LRB- B , D -RRB-	28621
OEC	28621
B , D	28626
B	28626
D	28629
sections	28632
Spherical Iba-1 immune cells	28642
distinct zones	28706
yellow arrows	28722
astrocyte processes in OEC - -LRB- B , D -RRB- but not FB-treated rats	28751
astrocyte processes in OEC - -LRB- B , D -RRB-	28751
astrocyte processes in OEC -	28751
astrocyte processes	28751
OEC	28774
B , D	28780
B	28780
D	28783
FB-treated rats	28794
A , C	28811
A	28811
C	28814
Astrocyte processes in FB-treated rats	28818
Astrocyte processes	28818
FB-treated rats	28841
parallel	28898
white arrowheads	28908
the scar border	28929
they	28953
yellow arrowheads	28994
OEC-treated rats	29016
Hoechst nuclear staining -LRB- yellow image -RRB-	29034
Hoechst nuclear staining	29034
yellow image	29060
an even	29080
Figure legend	29089
Figure 8 .	29116
Figure	29116
8	29123
CSA administration	29126
graft survival	29154
2 and 8 weeks postinjury	29172
A ` ÄìD	29198
CSA immunosuppression both FB -LRB- A , C -RRB- and OEC -LRB- B , D -RRB-	29210
CSA immunosuppression both FB	29210
A , C	29241
A	29241
C	29244
OEC	29251
B , D	29256
B	29256
D	29259
transplanted cells	29262
the lesion core -LRB- * -RRB-	29308
the lesion core	29308
2 weeks	29331
A , B	29340
A	29340
B	29343
8 weeks -LRB- C , D -RRB-	29369
8 weeks	29369
postinjury	29384
GFP-labeled cells	29396
the stumps -LRB- white arrows -RRB- and lesion core -LRB- white arrowheads -RRB-	29428
the stumps	29428
white arrows	29440
lesion core	29458
white arrowheads	29471
both FB - and OEC-treated rats	29492
both FB	29492
OEC-treated rats	29505
E	29523
Comparison	29526
the percentage of GFP in the lesion core of FB - -LRB- left , black -RRB-	29540
the percentage	29540
GFP in the lesion core of FB -	29558
GFP	29558
the lesion core	29565
FB	29584
black	29595
OEC	29606
green	29619
rats	29634
CSA -LRB- FB+CSA , orange ; OEC+CSA , purple -RRB-	29655
CSA	29655
FB+CSA , orange ; OEC+CSA , purple	29660
FB+CSA	29660
orange ; OEC+CSA	29668
orange	29668
OEC+CSA	29676
purple	29685
The volume of FBs and OECs in the lesion core	29694
The volume	29694
FBs and OECs in the lesion core	29708
FBs and OECs	29708
the lesion core	29724
CSA administration	29769
F , The difference in Iba-1 luminance in the stumps	29789
F	29789
The difference in Iba-1 luminance in the stumps	29792
The difference	29792
Iba-1 luminance in the stumps	29810
Iba-1 luminance	29810
the stumps	29829
the lesion core	29852
immune cell infiltration	29886
2 week CSA+FB	29924
non-CSA FB-treated rats	29947
The group	29972
Iba-l luminance	29991
OEC-treated rats	30010
CSA treatment	30047
Scale bars : A ` ÄìD , 1 mm .	30062
Scale bars	30062
A ` ÄìD , 1 mm	30074
A ` ÄìD	30074
1 mm	30081
Figure 9 .	30088
Figure	30088
9	30095
OEC survival in CSA-treated rats	30098
OEC survival	30098
CSA-treated rats	30114
neuronal degeneration	30139
serotonergic axonal preservation	30174
A , B , The same section	30208
B	30210
The same section	30213
A -LRB- red neurons and cyan GFAP scar border -RRB- andB	30248
A -LRB- red neurons and cyan GFAP scar border -RRB-	30248
A	30248
red neurons and cyan GFAP scar border	30251
red neurons	30251
cyan GFAP scar border	30267
red neurons and green OECs	30295
red neurons	30295
green OECs	30311
CSA and OEC treatment	30338
neurons -LRB- white arrows -RRB-	30361
neurons	30361
white arrows	30370
the astrocyte scar border -LRB- cyan -RRB-	30406
the astrocyte scar border	30406
cyan	30433
2weeks postinjury -LRB- A -RRB-	30442
2weeks postinjury	30442
A	30461
Neurons marked with white arrowheads -LRB- A , B -RRB-	30465
Neurons	30465
white arrowheads	30485
A , B	30503
A	30503
B	30506
the lesion core -LRB- * -RRB-	30521
the lesion core	30521
OECs -LRB- B , inset -RRB-	30563
OECs	30563
C	30580
Confocal 3D visualization	30583
neurofilament-labeled axons -LRB- red -RRB-	30612
neurofilament-labeled axons	30612
red	30641
the lesion core	30653
OECs in horizontal -LRB- white arrows -RRB-	30693
OECs	30693
horizontal -LRB- white arrows -RRB-	30701
horizontal	30701
white arrows	30713
cross-sectional -LRB- white arrowhead -RRB- orientation at 8 weeks postinjury	30731
cross-sectional -LRB- white arrowhead -RRB- orientation	30731
white arrowhead	30748
8 weeks postinjury	30780
an OEC+CSA	30802
rat.D	30821
E	30828
non-CSA-treated rats	30843
the number of 5-HT axons crossing the scar border	30865
the number	30865
5-HT axons crossing the scar border	30879
5-HT axons	30879
the scar border	30899
the area of 5-HT in the lesion core	30931
the area	30931
5-HT in the lesion core	30943
5-HT	30943
the lesion core	30951
FB+CSA - and OEC+CSA - treated rats at 2 weeks	30980
FB+CSA	30980
OEC+CSA	30992
rats	31008
2 weeks	31016
F	31025
The average distance	31028
the furthest extending 5-HT axon and the scar border	31057
the furthest	31057
5-HT axon and the scar border	31080
5-HT axon	31080
the scar border	31094
8-week OEC+CSA	31125
rats	31148
any other treatment group -LRB- FB , FB+CSA , OEC -RRB-	31158
any other treatment group	31158
FB , FB+CSA , OEC	31185
The mean luminance of CSPGs	31207
The mean luminance	31207
CSPGs	31229
the lesion core -LRB- G -RRB-	31250
the lesion core	31250
G	31267
stumps -LRB- H -RRB- of FB+CSA -LRB- orange -RRB-	31274
stumps -LRB- H -RRB-	31274
stumps	31274
H	31282
FB+CSA -LRB- orange -RRB-	31288
FB+CSA	31288
orange	31296
OEC+CSA -LRB- purple -RRB-	31312
OEC+CSA	31312
purple	31321
spinal cords	31337
2 and 8 weeks postinjury	31353
the lesion core -LRB- G -RRB-	31386
the lesion core	31386
G	31403
FB-treated rats	31407
levels of CSPGs with versus without CSA administration	31435
levels	31435
CSPGs with versus without CSA administration	31445
CSPGs	31445
CSA administration	31471
8 weeks	31493
OEC-treated rats	31510
lower levels of CSPGs	31531
lower levels	31531
CSPGs	31547
OEC+CSA	31558
rats	31574
2 weeks	31582
postinjury	31590
Scale bars : A , B , 500 ¬ µm ;	31602
Scale bars	31602
A , B , 500 ¬ µm	31614
A	31614
B	31616
500 ¬ µm	31619
50 ¬ µm ; C , 5 ¬ µm	31634
50 ¬ µm	31634
C , 5 ¬ µm	31641
C	31641
5 ¬ µm	31644
Figure 10 .	31651
Figure	31651
10	31658
CSA treatment	31662
OEC-mediated myelin uptake at 2 and 8 weeks postinjury	31685
OEC-mediated myelin uptake	31685
2 and 8 weeks postinjury	31715
Oil	31746
Red O-labeled myelin debris -LRB- red spheres -RRB-	31750
Red O-labeled myelin debris	31750
red spheres	31779
the lesion core -LRB- * -RRB-	31807
the lesion core	31807
stumps -LRB- brown , GFAP -RRB-	31831
stumps	31831
brown , GFAP	31839
brown	31839
GFAP	31846
FB+CSA -LRB- A , C -RRB- than OEC+CSA - treated spinal cords -LRB- B , D -RRB-	31855
FB+CSA -LRB- A , C -RRB-	31855
FB+CSA	31855
A , C	31863
A	31863
C	31866
OEC+CSA - treated spinal cords	31874
OEC+CSA	31874
spinal cords	31890
B , D	31904
B	31904
D	31907
A , B , Myelin debris -LRB- black arrows -RRB-	31911
A , B , Myelin debris	31911
B	31914
black arrows	31932
the stumps and lesion core	31966
FB+CSA	31996
OEC	32015
CSA-treated spinal cords	32020
2 weeks postinjury	32048
C , D ,	32068
C	32068
D	32071
8 weeks postinjury	32077
rats treated with FB+CSA	32097
rats	32097
FB+CSA	32115
more myelin debris present in the stumps	32126
more myelin debris	32126
the stumps	32156
those treated with OEC+CSA	32172
those	32172
OEC+CSA	32191
a ` Äìd , Enlarged images of the boxed areas -LRB- insets -RRB- in A ` ÄìD	32200
a ` Äìd	32200
Enlarged images of the boxed areas -LRB- insets -RRB- in A ` ÄìD	32207
Enlarged images	32207
the boxed areas -LRB- insets -RRB- in A ` ÄìD	32226
the	32226
areas -LRB- insets -RRB-	32236
areas	32236
insets	32243
A ` ÄìD	32254
more red punctate	32265
Oil Red O-staining in FB+CSA	32283
Oil Red O-staining	32283
FB+CSA	32305
OEC+CSA - treated spinal cords	32317
OEC+CSA	32317
spinal cords	32333
E , Orthogonal view of a Cell	32347
E , Orthogonal view	32347
a Cell	32369
Tracker Green-labeled OEC -LRB- green -RRB-	32376
Tracker Green-labeled OEC	32376
MBP-positive myelin debris -LRB- red , white arrowheads -RRB-	32424
MBP-positive myelin debris	32424
red , white arrowheads	32452
red	32452
white arrowheads	32457
Scale bars : A ` ÄìD , 1 mm ; a ` Äìd , 100 ¬ µm ; E , 5 ¬ µm .	32485
Scale bars	32485
A ` ÄìD , 1 mm	32497
A ` ÄìD	32497
1 mm	32504
a ` Äìd , 100 ¬ µm	32510
a ` Äìd	32510
100 ¬ µm	32517
E , 5 ¬ µm	32525
E	32525
5 ¬ µm	32528
Wild-type and GFP-OECs	32535
Wild-type	32535
GFP-OECs	32549
similar growth promoting abilities OECs are unique glia of the olfactory system	32563
similar growth	32563
abilities OECs are unique glia of the olfactory system	32588
abilities	32588
OECs	32598
unique glia of the olfactory system	32607
unique glia	32607
the olfactory system	32622
they	32648
markers	32661
astrocytes , oligodendrocytes , and Schwann cells	32679
No OEC-specific marker	32728
transplanted cells in this study	32787
transplanted cells	32787
this study	32809
we	32821
OECs	32832
GFPlabeled rats generated by random transgene integration into the genome	32842
GFPlabeled rats	32842
random transgene integration	32871
the genome	32905
OECs cultured from GFP-expressing rats -LRB- GFP-OECs -RRB-	32935
OECs	32935
GFP-expressing rats	32954
GFP-OECs	32975
those derived from wild-type nontransgenic rats	32999
those	32999
wild-type nontransgenic rats	33018
we	33048
GFP-OECs	33060
expression of typical markers	33073
expression	33073
typical markers	33087
Most GFP-OECs	33104
established OEC markers -LRB- 89 % p-75-NGFR ; 96 % S100 ; 100 % Sox10 -RRB-	33128
established OEC markers	33128
89 % p-75-NGFR ; 96 % S100 ; 100 % Sox10	33153
89 % p-75-NGFR	33153
96 % S100 ; 100 % Sox10	33168
96 % S100	33168
100 % Sox10	33178
We	33191
the growth	33208
abilities of wild-type OECs	33229
abilities	33229
wild-type OECs	33242
GFP-OECs	33262
We	33272
postnatal cortical neurons on	33284
postnatal cortical neurons	33284
-LRB- positive control -RRB-	33327
PLL	33351
-LRB- neutral substrate -RRB- ,	33355
-LRB- neutral substrate -RRB-	33355
-LRB- 3 -RRB- PLL and OEC , and -LRB- 4 -RRB- PLL and GFP-OEC	33376
-LRB- 3 -RRB- PLL and OEC	33376
PLL	33380
OEC	33388
-LRB- 4 -RRB- PLL and GFP-OEC	33397
PLL	33401
GFP-OEC	33409
Neurites	33418
processes	33437
laminin	33464
outgrowth on the PLL substrate	33489
outgrowth	33489
the PLL substrate	33502
neurite length on : laminin 146 ¬ ± 31 ¬ µm ; PLL 54 ¬	33532
neurite length on : laminin 146 ¬ ± 31 ¬ µm ; PLL 54	33532
neurite length on : laminin 146 ¬ ± 31 ¬ µm	33532
neurite length on : laminin 146 ¬	33532
neurite length	33532
laminin 146	33551
laminin	33551
146	33559
± 31 ¬ µm	33564
PLL 54	33574
9 ¬ µm	33584
p = 0.0014	33591
p	33591
0.0014	33595
The addition of OECs or GFP-OECs	33604
The addition	33604
OECs or GFP-OECs	33620
neurite outgrowth compared with PLL alone -LRB- OEC 117 ¬	33660
neurite outgrowth	33660
PLL	33692
alone -LRB- OEC 117 ¬	33696
alone -LRB- OEC 117	33696
alone	33696
OEC 117	33703
OEC	33703
117	33707
19 ¬ µm	33714
p = 0.0114 ; GFP-OECs 118 ¬ ± 29 ¬ µm	33722
p = 0.0114 ; GFP-OECs 118 ¬	33722
p	33722
0.0114 ; GFP-OECs 118 ¬	33726
0.0114 ; GFP-OECs 118	33726
0.0114	33726
GFP-OECs 118	33734
29	33750
¬ µm	33753
p	33758
0.0111	33762
neurite outgrowth	33779
OECs and GFP-OECs -LRB- p = 0.986 -RRB-	33820
OECs and GFP-OECs	33820
p	33839
0.986	33843
the random GFP gene insertion	33850
the growth promoting effects of OECs	33905
the growth	33905
effects of OECs	33926
effects	33926
OECs	33937
OECs	33943
FBs	33968
transplantation Transplanted FBs and OECs	33978
the GFAP-positive rostral	34047
caudal stumps	34080
the lesion core	34099
the first week postinjury -LRB- Fig. 1A , B ; Table 1 -RRB-	34122
the first week postinjury	34122
Fig. 1A , B ; Table 1	34149
Fig. 1A	34149
B ; Table 1	34157
B	34157
Table 1	34160
week 1	34177
the transplanted cells	34185
their differences	34240
size and cellular morphology	34261
size	34261
cellular morphology	34270
Fig. 1G , H	34291
Fig. 1G	34291
H	34299
Ovoid-shaped FBs	34303
a contiguous carpet-like arrangement	34327
a larger area	34375
spindle-shaped OECs that aligned into tubular networks -LRB- Fig. 1G , H -RRB-	34394
spindle-shaped OECs	34394
tubular networks	34432
Fig. 1G , H	34450
Fig. 1G	34450
H	34458
2 weeks	34465
there	34474
a clear loss of cells in the lesion core	34484
a clear loss	34484
cells in the lesion core	34500
cells	34500
the lesion core	34509
FBs and OECs	34528
the spinal cord stumps	34567
Fig. 1C , D	34591
Fig. 1C	34591
D	34599
GFPpositive debris	34617
the lesion core	34649
the stumps	34669
2 and 4 weeks postinjury	34683
2 and 4 weeks	34683
postinjury	34697
graft cell death	34725
4 weeks	34746
none of the rats transplanted with FBs	34755
none	34755
the rats transplanted with FBs	34763
the rats	34763
FBs	34790
GFP-labeled cells	34798
OECs	34825
five of eight rats -LRB- Fig. 1E , F -RRB-	34842
five	34842
eight rats -LRB- Fig. 1E , F -RRB-	34850
eight rats	34850
Fig. 1E , F	34862
Fig. 1E	34862
F	34870
those five rats with OECs	34877
those five rats	34877
OECs	34898
two rats	34904
OECs in the rostral	34917
OECs	34917
the rostral	34925
caudal stumps and three	34941
caudal stumps	34941
three	34959
the majority of OECs in the lesion core -LRB- Fig. 1F -RRB-	34969
the majority	34969
OECs in the lesion core -LRB- Fig. 1F -RRB-	34985
OECs	34985
the lesion core -LRB- Fig. 1F -RRB-	34993
the lesion core	34993
Fig. 1F	35010
more OECs	35035
the lesion core	35057
4 than at 2 weeks -LRB- Fig. 1 , compare D , F -RRB-	35076
4 than at 2 weeks	35076
Fig. 1 , compare D , F	35095
Fig. 1	35095
D , F	35111
D	35111
F	35114
a few OECs	35127
the stumps	35156
none	35172
the lesion core	35189
8 weeks -LRB- data not shown -RRB-	35208
8 weeks	35208
data not shown	35217
data	35217
These data	35234
OECs	35258
FBs	35283
transplantation	35293
FB and OEC survival and migration	35322
FB and OEC survival	35322
migration	35346
the volume	35357
GFP-labeled cells	35371
the lesion core divided by the total volume of GFP in the spinal cord	35392
the lesion core	35392
the total volume of GFP	35419
the total volume	35419
GFP	35439
the spinal cord	35446
a percentage	35478
1	35495
week	35497
a large percentage of the GFP-labeled cells	35502
a large percentage	35502
the GFP-labeled cells	35524
in the lesion core -LRB- Fig. 1J ; FB 72 ¬ ± 5 % vs OEC 79 ¬	35557
in the lesion core -LRB- Fig. 1J ; FB 72 ¬ ± 5 % vs OEC 79	35557
in the lesion core -LRB- Fig. 1J ; FB 72 ¬ ± 5 %	35557
the lesion core -LRB- Fig. 1J ; FB 72 ¬ ±	35560
the lesion	35560
core -LRB- Fig. 1J ; FB 72 ¬ ±	35571
core -LRB- Fig. 1J ; FB 72 ¬	35571
core	35571
Fig. 1J ; FB 72 ¬	35577
Fig.	35577
1J ; FB 72 ¬	35582
1J ; FB 72	35582
1J	35582
FB 72	35586
OEC 79	35601
4 %	35611
The decrease in survival of transplanted cells in the lesion core at 2 weeks	35616
The decrease	35616
survival of transplanted cells in the lesion core at 2 weeks	35632
survival	35632
transplanted cells in the lesion core at 2 weeks	35644
transplanted cells	35644
the lesion core	35666
at 2 weeks	35682
remarkable -LRB- Fig. 1J ; FB 3 ¬ ±	35697
remarkable -LRB- Fig. 1J ; FB 3 ¬	35697
remarkable	35697
Fig. 1J ; FB 3 ¬	35709
Fig.	35709
1J ; FB 3 ¬	35714
1J	35714
FB 3	35718
FB	35718
3	35721
3 % vs OEC 14 ¬ ± 7 %	35726
3 % vs OEC 14 ¬	35726
3 %	35726
vs OEC 14 ¬	35729
vs OEC 14	35729
vs OEC	35729
14	35736
7 %	35742
4 weeks	35750
GFP-labeled cells	35759
only in the lesion core of OECtreated rats -LRB- Fig. 1J ; FB 0 % vs OEC 23 ¬	35788
only in the lesion core of OECtreated rats -LRB- Fig. 1J ; FB 0 % vs OEC 23	35788
the lesion core of OECtreated rats -LRB- Fig. 1J ;	35796
the lesion core	35796
OECtreated rats -LRB- Fig. 1J ;	35815
OECtreated rats	35815
Fig. 1J	35832
FB 0 %	35841
FB	35841
0 %	35844
OEC 23	35850
OEC	35850
23	35854
14 %	35860
p = 0.0381	35865
p	35865
0.0381	35869
This finding	35878
OECs	35906
the lesion core between 2 and 4 weeks	35936
the lesion core	35936
2 and 4 weeks	35960
the lesion core	35983
FBs	36000
a continuous sheet of cells	36011
a continuous sheet	36011
cells	36033
OECs	36048
delicate trabecular-like networks -LRB- Fig. 1G ` ÄìI -RRB-	36067
delicate trabecular-like networks	36067
Fig. 1G ` ÄìI	36102
Fig. 1G	36102
` ÄìI	36109
the extent	36128
FBs and OECs	36144
the lesion core	36164
the volume of GFP-labeled cells	36181
the volume	36181
GFP-labeled cells	36195
the volume of the fibronectin-positive extracellular matrix in the lesion core	36228
the volume	36228
the fibronectin-positive extracellular matrix in the lesion core	36242
the fibronectin-positive extracellular matrix	36242
the lesion core	36291
a percentage	36323
FBs	36337
âà83	36349
17 %	36356
the lesion at 1	36363
the lesion	36363
1	36377
week	36379
2 weeks	36392
few FBs	36400
3 * 3 %	36418
3 * 3	36418
3	36418
3	36421
%	36422
OECs	36426
34	36438
6 % of the lesion volume	36441
6 %	36441
the lesion volume	36447
1 week	36468
2 weeks	36483
âà1 % of the lesion volume	36498
âà1 %	36498
the lesion volume	36506
OECs	36534
4 weeks	36558
the stumps	36592
the lesion core	36608
they	36627
8 ¬	36643
8	36643
5 %	36648
the lesion volume	36654
These data	36673
FBs	36697
more of the lesion core	36716
more	36716
the lesion core	36724
OECs	36745
this difference	36755
time	36794
OECs	36800
neuronal degeneration	36812
a spinal cord transection	36840
We	36866
OEC transplantation	36888
long lasting effects on neuronal survival	36912
long lasting effects	36912
neuronal survival	36936
OECs	36976
neurons	36995
we	37004
the shortest distance	37016
the astroglial scar border and NeuN-labeled neuronal cell bodies	37046
the astroglial scar border	37046
NeuN-labeled neuronal cell bodies	37077
the rostral and caudal stumps -LRB- Fig. 2A -RRB-	37114
the rostral	37114
caudal stumps -LRB- Fig. 2A -RRB-	37130
caudal stumps	37130
Fig. 2A	37145
The distance between the GFAP border and the nearest neuron	37155
The distance	37155
the GFAP border and the nearest neuron	37176
the GFAP border	37176
the nearest neuron	37196
the rostral and caudal stumps	37238
the rostral	37238
caudal stumps	37254
values from the two stumps	37277
values	37277
the two stumps	37289
the average neuron-free distance	37328
the stumps	37364
Neuronal cell	37376
bodies	37390
the astroglial scar	37420
border	37440
OEC	37450
FB-transplanted rats at 1 and 2 weeks -LRB- Fig. 2C ; 1 week FB 1.2 ¬ ±	37463
FB-transplanted rats	37463
1 and 2 weeks -LRB- Fig. 2C ; 1 week FB 1.2 ¬	37487
1	37487
2 weeks -LRB- Fig. 2C ; 1 week FB 1.2 ¬	37493
2 weeks	37493
Fig. 2C ; 1 week FB 1.2 ¬	37502
Fig. 2C	37502
1 week FB 1.2 ¬	37511
1 week	37511
FB 1.2 ¬	37518
FB 1.2	37518
FB	37518
1.2	37521
0.1 vs OEC	37528
0.1	37528
OEC	37535
0.1	37546
mm , p = 0.0502 ; 2 week FB 1.9 ¬	37550
mm	37550
p = 0.0502 ; 2 week FB 1.9 ¬	37554
p	37554
0.0502 ; 2 week FB 1.9 ¬	37558
0.0502 ; 2 week FB 1.9	37558
0.0502	37558
2 week FB 1.9	37566
2 week	37566
FB 1.9	37573
0.5	37583
OEC 0.6	37590
0.2	37601
mm , p = 0.0004	37605
mm	37605
p = 0.0004	37609
p	37609
0.0004	37613
addition	37625
the first 2 weeks	37642
the total distance between the closest rostral and caudal stump neurons	37660
the total distance	37660
the closest rostral and caudal stump neurons	37687
the closest rostral	37687
caudal stump neurons	37711
shorter	37736
FB-treated spinal cords -LRB- Fig. 2D ;	37764
FB-treated spinal cords	37764
Fig. 2D	37789
1 week FB	37798
7.2 ¬ ± 0.3 vs OEC 5.2 ¬ ± 0.3 mm , p = 0.0024 ; 2 week FB 7.4 ¬ ± 1 vs OEC 4.1	37808
7.2 ¬ ± 0.3 vs OEC 5.2 ¬ ± 0.3 mm , p = 0.0024 ; 2 week FB 7.4 ¬	37808
7.2 ¬ ± 0.3	37808
7.2 ¬	37808
± 0.3	37812
OEC 5.2 ¬ ± 0.3 mm , p = 0.0024 ; 2 week FB 7.4 ¬	37821
OEC 5.2 ¬ ±	37821
0.3 mm , p = 0.0024 ; 2 week FB 7.4 ¬	37830
0.3 mm , p = 0.0024 ; 2 week FB 7.4	37830
0.3 mm	37830
p = 0.0024 ; 2 week FB 7.4	37838
p = 0.0024	37838
p	37838
0.0024	37840
2 week FB 7.4	37848
2 week	37848
FB 7.4	37855
1 vs OEC 4.1	37863
1 vs	37863
OEC 4.1	37868
0.6 mm	37879
p = 0.0272	37887
p	37887
0.0272	37891
the extent of neuronal survival	37909
the extent	37909
neuronal survival	37923
transplant groups	37964
4 weeks	37985
we	37994
spinal cord neurons ensheathed by GFP-positive OECs	38006
spinal cord neurons	38006
GFP-positive OECs	38040
FBs in the lesion core -LRB- Fig. 2B -RRB-	38066
FBs	38066
the lesion core -LRB- Fig. 2B -RRB-	38073
the lesion core	38073
Fig. 2B	38090
OEC transplantation	38106
neuronal survival	38135
the stumps	38156
the surviving neurons	38180
the lesion core	38209
OEC transplants	38226
axonal dieback	38249
a spinal cord transection	38270
a spinal cord injury	38314
astrocytes	38336
their processes to seal off the lesion	38374
the lesion	38402
the ` Äúpathways	38431
Äù	38447
routes for regenerating axons	38482
routes	38482
regenerating axons	38493
Li	38513
et al. , 2005b	38516
et al.	38516
2005b	38524
OEC transplantation	38557
axons we identified the raphespinal tract	38592
axons	38592
we	38598
the raphespinal tract	38612
ie , descending serotonergic -LRB- 5-HT -RRB-	38635
ie , descending serotonergic	38635
5-HT	38664
important for locomotion , in FB - and OEC-treated spinal cords	38676
locomotion	38690
FB	38705
we	38750
5-HT axons	38764
the rostral stump	38789
the lesion core	38812
a complete spinal cord transection	38834
the raphespinal tract thanintraspinal5-HTneurons	38893
Takeokaet	38942
al. , 2011	38952
al.	38952
2011	38957
OEC treatment	38974
multiple 5-HT axons	38989
astrocytes at the GFAP-positive border -LRB- Fig. 3C , D -RRB-	39037
astrocytes	39037
the GFAP-positive border -LRB- Fig. 3C , D -RRB-	39051
the GFAP-positive border	39051
Fig. 3C , D	39077
Fig. 3C	39077
D	39085
These 5-HT bundles	39089
astrocytes	39119
processes that effectively provide ` Äúpathways ` Äù	39167
processes	39167
Äúpathways ` Äù	39203
Äúpathways	39203
Äù	39214
severed axonstoregenerate -LRB- Fig. 3C , D -RRB-	39221
severed axonstoregenerate	39221
Fig. 3C , D	39247
Fig. 3C	39247
D	39254
FB-treated spinal cords	39271
astrocytic processes	39295
the rostrocaudal axis	39346
the extension of 5-HT axons	39389
the extension	39389
5-HT axons	39406
the lesion core -LRB- Fig. 3A , B -RRB-	39422
the lesion core	39422
Fig. 3A , B	39439
Fig. 3A	39439
B	39447
We	39451
the total number	39465
5-HT axons	39485
astrocytes	39514
the scar border	39537
fewer axons	39563
FB	39578
OEC groups	39586
time points -LRB- FB 8 ¬ ±	39617
time points -LRB- FB 8 ¬	39617
time	39617
points -LRB- FB 8 ¬	39622
points -LRB- FB 8	39622
points	39622
FB 8	39630
FB	39630
8	39633
7 vs OEC 31 ¬	39636
7 vs OEC 31	39636
7	39636
OEC 31	39641
14 axons	39649
p = 0.0045	39659
p	39659
0.0045	39662
the first week	39674
the total number	39689
5-HTaxons	39709
twofold greater inOEC-than FB-treated rats -LRB- Fig. 3G ; FB 29 ¬ ±	39723
twofold greater inOEC-than FB-treated rats -LRB- Fig. 3G ; FB 29 ¬	39723
twofold greater inOEC-than	39723
FB-treated rats -LRB- Fig. 3G ; FB 29 ¬	39750
FB-treated rats	39750
Fig. 3G ; FB 29 ¬	39767
Fig.	39767
3G ; FB 29 ¬	39772
3G ; FB 29	39772
3G	39772
FB 29	39776
9 vs OEC 72 ¬	39785
9 vs OEC 72	39785
9	39785
OEC 72	39790
22	39798
axons , p 0.0045	39801
axons	39801
p 0.0045	39808
axons	39824
the rostral border	39843
OEC	39865
FBtreated rats at 2 weeks -LRB- Fig. 3G ; FB 1 ¬ ± 1 vs OEC 32	39875
FBtreated rats at 2 weeks -LRB- Fig. 3G ; FB 1 ¬ ±	39875
FBtreated rats	39875
2 weeks -LRB- Fig. 3G ; FB 1 ¬	39893
2	39893
weeks -LRB- Fig. 3G ; FB 1 ¬	39895
weeks -LRB- Fig. 3G ; FB 1	39895
weeks	39895
Fig. 3G ; FB 1	39902
Fig. 3G	39902
FB 1	39911
1 vs OEC 32	39919
1	39919
OEC 32	39924
6 axons	39932
p = 0.0231	39941
p	39941
0.0231	39943
This finding	39952
OECs	39979
5-HT axons	39993
the configuration of astrocytes at the scar border	40020
the configuration	40020
astrocytes at the scar border	40041
astrocytes	40041
the scar border	40055
the extension of 5-HT axons	40082
the extension	40082
5-HT axons	40099
the lesion core	40115
addition to the number of 5-HT axons that crossed the astrocyte border	40135
addition	40135
the number of 5-HT axons that crossed the astrocyte border	40147
the number	40147
5-HT axons	40161
the astrocyte border	40185
we	40207
more 5-HT axons	40229
the lesion core of OEC	40259
the lesion core	40259
OEC	40278
FBtreated rats	40288
individual 5-HT axons	40312
we	40370
the area of the lesion core that contained 5-HT axons	40382
the area	40382
the lesion core	40394
5-HT axons	40425
Larger areas	40437
the OEC	40453
the FB	40466
lesion cores	40473
5-HTpositive axons at 2 weeks -LRB- Fig. 3A , B ; FB 781 ¬ ±	40490
5-HTpositive axons at 2 weeks -LRB- Fig. 3A , B ; FB 781 ¬	40490
5-HTpositive axons	40490
2 weeks -LRB- Fig. 3A , B ; FB 781	40512
2 weeks -LRB- Fig. 3A , B	40512
Fig. 3A	40521
B	40529
FB 781	40532
641 vs OEC 12,020 ¬	40542
641 vs OEC 12,020	40542
641	40542
OEC 12,020	40549
5342 ¬	40563
µm2 , p = 0.0267	40569
µm2	40569
p = 0.0267	40574
p	40574
0.0267	40576
Wealso	40584
the lesion core	40613
the 5-HT axons	40629
We	40655
the distance between the most caudal 5-HT axon and the rostral GFAP-border	40667
the distance	40667
the most caudal 5-HT axon and the rostral GFAP-border	40688
the most caudal 5-HT axon	40688
the rostral GFAP-border	40718
average	40746
5-HT axons	40755
the lesion core	40797
OEC	40816
FBtreated cords at 1 week -LRB- Fig. 3H ; FB 173 ¬ ± 38 vs OEC 438 ¬ ± 172 ¬ µm	40835
FBtreated cords at 1 week -LRB- Fig. 3H ; FB 173 ¬ ± 38	40835
FBtreated cords at 1 week -LRB- Fig. 3H ; FB 173 ¬ ±	40835
FBtreated cords	40835
1 week -LRB- Fig. 3H ; FB 173 ¬	40854
1	40854
week -LRB- Fig. 3H ; FB 173 ¬	40856
week -LRB- Fig. 3H ; FB 173	40856
week	40856
Fig. 3H ; FB 173	40862
Fig. 3H	40862
FB 173	40871
38	40881
OEC 438 ¬ ± 172 ¬ µm	40887
OEC 438 ¬ ±	40887
172 ¬ µm	40898
p = 0.0757	40907
p	40907
0.0757	40911
2 weeks	40923
the 5-HT axons in FB-treated rats	40932
the 5-HT axons	40932
FB-treated rats	40950
dieback	40976
the rostral stump	40989
a negative value	41023
they	41049
the lesion	41076
core of OEC-treated rats -LRB- Fig. 3H ; FB 371 ¬ ± 161	41087
core of OEC-treated rats -LRB- Fig. 3H ; FB 371 ¬	41087
core	41087
OEC-treated rats -LRB- Fig. 3H ; FB 371	41095
OEC-treated rats	41095
Fig. 3H	41113
FB 371	41122
161	41130
vs OEC 227 ¬	41134
vs OEC 227	41134
vs OEC	41134
± 76 ¬ µm	41145
p = 0.0001	41153
p	41153
0.0001	41157
4 weeks	41169
the 5-HT axons that extended beyond the astroglial scar border	41178
the 5-HT axons	41178
the astroglial scar border	41214
OECs -LRB- Fig. 3E -RRB-	41254
OECs	41254
Fig. 3E	41260
We	41270
anti-NF-H	41283
axons	41305
the injury site	41314
groups of OECs	41345
groups	41345
OECs	41355
bundles	41377
axons that extended past the rostral scar border at 4 weeks -LRB- Fig. 3F -RRB-	41388
axons	41388
the rostral scar border	41413
4 weeks -LRB- Fig. 3F -RRB-	41440
4 weeks	41440
Fig. 3F	41449
reactive scar-forming astrocytes	41473
scaffolds	41515
OECs and axons	41529
the lesion core -LRB- Fig. 3F -RRB-	41564
the lesion core	41564
Fig. 3F	41581
sum	41594
these data	41599
OECs	41623
axons	41642
the lesion core	41651
axonal dieback	41675
FBs	41704
extensions of astrocytes	41718
extensions	41718
astrocytes	41732
the scar border to provide pathways for axons to enter the lesion core	41746
pathways for axons	41773
pathways	41773
axons	41786
the lesion core	41801
OECs	41818
inhibitory factors	41830
the injury site	41852
OECs	41889
the inhibitory environment of the injury site	41901
the inhibitory environment	41901
the injury site	41931
we	41948
they	41960
inhibitory factors , such as CSPGs and myelin debris	41978
inhibitory factors	41978
CSPGs and myelin debris	42006
CSPGs	42006
myelin debris	42016
We	42031
CSPGs in the lesion core	42082
CSPGs	42082
the lesion core	42091
adjacent astroglial scar border in FB	42111
adjacent astroglial scar border	42111
FB	42146
OEC-treated spinal cords	42154
the lesion core	42191
the mean CS-56 luminance	42208
greater	42237
FB	42248
OEC-treated rats across all time-points -LRB- FB 3.2 ¬ ± 0.2 vs OEC 1.6	42257
OEC-treated rats across all time-points -LRB- FB 3.2 ¬ ±	42257
OEC-treated rats	42257
all time-points -LRB- FB 3.2 ¬	42281
all	42281
time-points -LRB- FB 3.2 ¬	42285
time-points -LRB- FB 3.2	42285
time-points	42285
FB 3.2	42298
FB	42298
3.2	42301
0.2 vs OEC 1.6	42306
0.2	42306
OEC 1.6	42313
0.1	42324
p = 0.0001	42329
p	42329
0.0001	42333
Measurements	42342
the mean	42358
CS-56 values	42367
a similar cell transplant effect in the rostral and caudal stumps -LRB- FB 2.2 ¬	42388
a similar cell transplant effect	42388
the rostral and caudal stumps -LRB- FB 2.2	42424
the rostral	42424
caudal stumps -LRB- FB 2.2	42440
caudal stumps	42440
FB 2.2	42455
FB	42455
2.2	42458
0.1 vs OEC 1.2 ¬	42465
0.1 vs OEC 1.2	42465
0.1	42465
OEC 1.2	42472
0.1	42483
p	42488
= 0.0001	42490
=	42490
0.0001	42492
the difference in CSPG expression	42512
the difference	42512
CSPG expression	42530
time	42551
we	42557
CS-56 immunoreactivity	42569
different time-points	42595
The mean	42618
CS-56 luminance	42627
greater	42647
the lesion core	42658
FBversus	42677
OEC-treated spinal cords	42686
2	42714
Fig. 4A ` ÄìC	42717
Fig. 4A	42717
` ÄìC	42724
4	42731
8 weeks postinjury -LRB- Fig. 4C ; 2 week FB 3.2 ¬	42738
8 weeks	42738
postinjury -LRB- Fig. 4C ; 2 week FB 3.2 ¬	42746
postinjury -LRB- Fig. 4C ; 2 week FB 3.2	42746
postinjury	42746
Fig. 4C ; 2 week FB 3.2	42758
Fig. 4C	42758
2 week FB 3.2	42767
2 week	42767
FB 3.2	42774
0.1	42784
OEC 1.2	42791
0.1	42802
p = 0.0001	42807
p	42807
0.0001	42811
4 week FB 2.7 ¬ ± 0.3 vs OEC 1.9 ¬ ± 0.1 , p = 0.0218	42819
4 week FB 2.7 ¬ ± 0.3 vs OEC 1.9 ¬ ± 0.1	42819
4 week FB	42819
2.7 ¬ ± 0.3 vs OEC 1.9 ¬ ± 0.1	42829
2.7 ¬ ± 0.3 vs OEC 1.9 ¬	42829
2.7 ¬	42829
± 0.3 vs OEC 1.9 ¬	42833
± 0.3 vs OEC 1.9	42833
± 0.3	42833
OEC 1.9	42841
0.1	42850
p = 0.0218	42855
p	42855
0.0218	42857
8 week FB 3.9 0.5 vs OEC 1.4	42865
8 week FB 3.9 0.5	42865
8 week FB	42865
OEC 1.4	42888
0.2 , p ` â † 0.0013	42899
0.2 , p ` â †	42899
0.2	42899
p ` â †	42904
0.0013	42910
The lesion core	42919
more CS-56 immunoreactivity	42945
the spinal cord stumps	42978
the rostral and caudal stump	43014
the rostral	43014
caudal stump	43030
borders	43043
CSPG	43052
levels	43057
higher	43069
FB	43079
OEC-treated spinal cords at 2 and 4 weeks -LRB- Fig. 4A , B , D ; 2 week	43088
OEC-treated spinal cords	43088
2 and 4 weeks -LRB- Fig. 4A , B , D ;	43116
2 and 4 weeks	43116
Fig. 4A	43131
B , D	43139
B	43139
D	43141
2 week	43144
FB 2.7	43151
0.1 vs OEC 1.2 ¬	43159
0.1 vs OEC 1.2	43159
0.1	43159
OEC 1.2	43166
0.1	43175
p = 0.0001	43180
p	43180
0.0001	43183
4 week FB 2.1 ¬ ± 0.3 vs OEC 1.3 ¬	43191
4 week FB	43191
2.1 ¬ ± 0.3 vs OEC 1.3 ¬	43201
2.1 ¬	43201
± 0.3 vs OEC 1.3 ¬	43206
± 0.3 vs OEC 1.3	43206
± 0.3	43206
OEC 1.3	43215
0.1	43226
p = 0.0002	43231
p	43231
0.0002	43235
a control	43247
GFAP luminance	43258
the same regions in each section	43291
the same regions	43291
each section	43311
FB and OEC groups -LRB- data not shown -RRB-	43351
FB and OEC groups	43351
data not shown	43370
data	43370
luminance intensity	43398
a reliable measure	43432
differences in CSPG levels between FB and OEC transplanted rats	43469
differences	43469
CSPG levels between FB and OEC transplanted rats	43484
CSPG levels	43484
FB and OEC transplanted rats	43504
FB	43504
OEC transplanted rats	43511
we	43539
the areas	43554
transplanted FBs or OECs	43576
different levels of CSPG luminance	43608
different levels	43608
CSPG luminance	43628
the lesion core and stumps	43646
the lesion core	43646
stumps	43666
2 weeks	43677
we	43686
a 50 % reduction	43695
CS-56	43714
luminance	43720
areas directly occupied by OECs	43733
areas	43733
OECs	43760
those	43773
FBs -LRB- Fig. 4A ,	43795
FBs	43795
Fig. 4A	43800
B , red channel	43808
B	43808
red channel	43811
lesion core	43824
lesion	43824
core	43831
FB 1.1 0.2 vs OEC 0.5 ¬ ± 0 , p = 0.0415 ; stumps : FB 1.1 ¬ ± 0.1 vs OEC 0.49	43837
FB 1.1 0.2	43837
FB	43837
1.1 0.2	43840
OEC 0.5 ¬ ± 0 , p = 0.0415 ; stumps : FB 1.1 ¬ ± 0.1 vs OEC 0.49	43853
OEC 0.5 ¬ ± 0 , p = 0.0415 ; stumps : FB 1.1 ¬ ± 0.1	43853
OEC 0.5 ¬ ±	43853
0	43864
p = 0.0415 ; stumps : FB 1.1 ¬ ± 0.1	43867
p = 0.0415 ; stumps : FB 1.1 ¬	43867
p	43867
0.0415 ; stumps : FB 1.1 ¬	43871
0.0415 ; stumps : FB 1.1	43871
0.0415	43871
stumps : FB 1.1	43879
stumps	43879
FB 1.1	43887
0.1	43897
OEC 0.49	43904
0.01	43916
p 0.0398	43922
the astrocytic border	43950
FB-transplanted rats	43989
higher levels of CSPG-labeling	44014
higher levels	44014
CSPG-labeling	44031
the presence of FBs	44061
the presence	44061
FBs	44077
OECs -LRB- Fig. 4A , B -RRB-	44086
OECs	44086
Fig. 4A , B	44092
Fig. 4A	44092
B	44100
the stumps of OEC-treated spinal cords	44107
the stumps	44107
OEC-treated spinal cords	44121
astrocyte processes	44147
CSPG-labeled cells	44193
cavities	44219
Fig. 4B , yellow arrowheads	44229
Fig. 4B	44229
yellow arrowheads	44238
OECs	44264
inhibitory CSPGs	44276
the injury site compared with FBs	44296
the injury site	44296
FBs	44326
The altered astrocyte border formation seen in FB-treated rats	44331
The altered astrocyte border formation	44331
FB-treated rats	44378
the comparison of astrocyte orientation and arrangement	44403
the comparison	44403
astrocyte orientation and arrangement	44421
the transplant groups	44467
A closer examination	44490
astrocytes	44514
both AQP4 and GFAP -LRB- Wanner et al. , 2013 -RRB-	44542
both AQP4 and GFAP	44542
Wanner	44562
et al. , 2013	44569
et al.	44569
2013	44577
GFP-labeled cells at the scar borders	44588
GFP-labeled cells	44588
the scar borders	44609
astrocytic processes	44640
direct contact with FBs compared with OECs -LRB- Fig. 4E , F -RRB-	44692
direct contact	44692
FBs compared with OECs -LRB- Fig. 4E , F -RRB-	44712
FBs	44712
OECs -LRB- Fig. 4E , F -RRB-	44730
OECs	44730
Fig. 4E , F	44736
Fig. 4E	44736
F	44744
OEC-treated spinal cords	44751
astrocytic processes	44776
a palisading arrangement	44802
OECs -LRB- Fig. 4F -RRB-	44848
OECs	44848
Fig. 4F	44854
The disorganized astrocytes that interact with FBs	44864
The disorganized astrocytes	44864
FBs	44911
highly fibronectinpositive areas -LRB- Fig. 4E -RRB-	44928
highly fibronectinpositive areas	44928
Fig. 4E	44962
Low levels of fibronectin - or CSPG-positive cells	44972
Low levels	44972
fibronectin - or CSPG-positive cells	44986
sequestered inOEC-but	45031
FB-treated spinal cords -LRB- Fig. 4A , B , E , F -RRB-	45057
FB-treated spinal cords	45057
Fig. 4A	45082
B , E , F	45090
These data	45098
the astroglial scar border forms	45120
FB transplantation	45170
OECs	45211
the presence of myelin debris	45228
the presence	45228
myelin debris	45244
the injury site	45272
we	45289
Oil Red O , a histological	45297
Oil Red O	45297
a histological	45308
neutral lipids including myelin debris	45345
neutral lipids	45345
myelin debris	45370
we	45399
more punctate Oil Red O-staining in FB - than OEC-treated rats	45408
more punctate Oil Red O-staining	45408
FB	45444
OEC-treated rats	45453
Myelin debris	45471
the rostral and caudal stumps of FB	45507
the rostral	45507
caudal stumps of FB	45523
caudal stumps	45523
FB	45540
OEC-treated spinal cords	45549
2 weeks -LRB- Fig. 5A , B -RRB-	45577
2 weeks	45577
Fig. 5A , B	45586
Fig. 5A	45586
B	45594
Oil Red O particulates	45598
the stumps	45647
the lesion core of FB	45682
the lesion core	45682
FB	45701
OEC-treated rats -LRB- Fig. 5a , b -RRB-	45719
OEC-treated rats	45719
Fig. 5a , b	45737
Fig. 5a	45737
b	45745
Myelin debris	45749
FB	45776
OEC-treated spinal cords	45788
4 and 8 weeks	45816
Fig. 5C ` ÄìF	45831
Fig. 5C	45831
` ÄìF	45838
more demyelination	45861
FB	45883
OEC-treated spinal cords	45892
combination	45921
OEC transplantation	45934
two components of the inhibitory environment	45965
two components	45965
the inhibitory environment	45983
the lesion site , CSPGs and myelin debris	46013
the lesion site	46013
CSPGs	46030
myelin debris	46040
OECs	46055
immune cell activation and infiltration	46067
a complete spinal cord transection	46113
Our results	46148
OECs	46173
the survival of neurons and limit dieback of 5-HT axons	46186
the survival	46186
neurons and limit dieback	46202
5-HT axons	46231
yet very few OECs	46243
8 weeks	46269
injury	46283
Cell transplantation therapies	46291
the immune response	46348
1 and 8 weeks after a spinal cord injury -LRB- Beck et al. , 2010 -RRB-	46382
1 and 8 weeks	46382
a spinal cord injury -LRB- Beck et al. , 2010 -RRB-	46402
a spinal cord injury	46402
Beck	46424
et al. , 2010	46429
et al.	46429
2010	46437
the interactions between transplant survival	46456
the interactions	46456
transplant survival	46481
macrophages and astrocytes	46527
antibodies	46555
calciumbinding adaptor molecule-1 -LRB- Iba-1 -RRB- and a GFAP control	46582
calciumbinding adaptor molecule-1 -LRB- Iba-1 -RRB-	46582
calciumbinding adaptor molecule-1	46582
Iba-1	46617
a GFAP control	46628
We	46658
the mean Iba-1 and GFAP luminance in five zones	46670
the mean Iba-1 and GFAP luminance	46670
five zones	46707
the rostral and caudal scar borders and stumps	46719
the rostral	46719
caudal scar borders and stumps	46735
the lesion core -LRB- Fig. 6A -RRB-	46771
the lesion core	46771
Fig. 6A	46788
Iba-1 levels in the lesion core	46798
Iba-1 levels	46798
the lesion core	46814
FB - and OEC-transplanted rats	46853
1 , 2 , 4 , and 8 weeks -LRB- data not shown -RRB-	46886
1 , 2 , 4 , and 8 weeks	46886
1	46886
2	46889
4	46892
8 weeks	46899
data not shown	46908
data	46908
A sharp increase in Iba-1 luminance	46925
A sharp increase	46925
Iba-1 luminance	46945
the rostral border and stump of FB	46987
the rostral border and stump	46987
FB	47019
OEC-treated rats	47037
2 weeks	47057
Fig. 6B	47066
D	47074
border FB 3.1 0.6 vs OEC 1.3 0.3 , p 0.0106 ; stump FB 3.1 0.6 vs OEC 1.3 0.3	47077
border FB 3.1 0.6	47077
border FB	47077
3.1 0.6	47087
OEC 1.3 0.3 , p 0.0106 ; stump FB 3.1 0.6 vs OEC 1.3 0.3	47100
OEC 1.3 0.3 , p 0.0106	47100
OEC 1.3 0.3	47100
OEC	47100
p 0.0106	47115
stump FB 3.1 0.6 vs OEC 1.3 0.3	47127
stump FB 3.1 0.6	47127
stump FB	47127
3.1 0.6	47136
OEC 1.3 0.3	47149
OEC	47149
p 0.0039	47164
Iba-1 levels	47177
the caudal stump of FB	47211
the caudal stump	47211
FB	47231
OEC-treated rats	47249
2 weeks -LRB- Fig. 6E ; stump FB 3.0 0.4 vs OEC 1.8 0.3 , p 0.0318 -RRB-	47269
2 weeks	47269
Fig. 6E ; stump FB 3.0 0.4 vs OEC 1.8 0.3 , p 0.0318	47278
Fig. 6E	47278
stump FB 3.0 0.4 vs OEC 1.8 0.3 , p 0.0318	47287
stump FB 3.0 0.4	47287
stump FB	47287
3.0 0.4	47296
OEC 1.8 0.3 , p 0.0318	47309
OEC 1.8 0.3	47309
OEC	47309
p 0.0318	47324
OEC-transplanted spinal cords	47340
the increase in Iba-1 levels	47370
the increase	47370
Iba-1 levels	47386
1 and 2 weeks in the rostral	47419
1 and 2 weeks	47419
the rostral	47436
not the caudal border and stump -LRB- Fig. 6 ,	47453
not the caudal border	47453
stump -LRB- Fig. 6 ,	47479
stump	47479
Fig. 6	47486
Fig.	47486
6	47491
slopes in B , D to C , E -RRB-	47502
slopes	47502
B , D to C , E -RRB-	47512
B	47512
E	47521
4 and 8 weeks	47528
the Iba-1 levels in the borders and stumps	47542
the Iba-1 levels	47542
the borders and stumps	47562
the FB andOECgroups	47606
Fig. 6B ` ÄìE	47627
Fig. 6B	47627
` ÄìE	47634
a control	47644
GFAP luminance	47655
the same five zones	47688
Figure 6A	47722
FB and OEC groups	47759
data not shown	47778
data	47778
These trends	47795
OECs delay	47821
the initial activation of Iba-1-positive immune cells	47843
the initial activation	47843
Iba-1-positive immune cells	47869
GFAP luminance measurements	47907
FB or OEC transplantation	47953
a close examination of the scar borders	47980
a close examination	47980
the scar borders	48003
differences	48029
The astroglial scar border	48042
2 weeks postinjury	48089
all transplanted rats	48111
the orientation and arrangement of astrocytic processes	48138
the orientation and arrangement	48138
astrocytic processes	48173
transplant group	48204
Fig. 7A ` ÄìD	48222
Fig. 7A	48222
` ÄìD	48229
FB-treated rats	48239
astrocytic processes	48256
peripheral cells	48330
more diffuse globoid Iba-1-positive cells	48361
the GFAP-positive scar	48410
Fig. 7A , C	48441
Fig. 7A	48441
C	48449
contrast	48456
astrocyte processes	48466
a distinctive barrier	48493
globoid Iba-1-positive immune cells	48546
OEC-treated spinal cords -LRB- Fig. 7B , D -RRB-	48585
OEC-treated spinal cords	48585
Fig. 7B , D	48611
Fig. 7B	48611
D	48619
Hoechst nuclear staining	48623
the astrocytic border formation	48671
FB	48720
OEC-treated rats -LRB- Fig. 7A ` ÄìD , individual channel images -RRB-	48738
OEC-treated rats	48738
Fig. 7A	48756
` ÄìD , individual channel images	48763
` ÄìD	48763
individual channel images	48769
immune cell infiltration	48825
cell transplantation type	48860
we	48887
the differences	48899
mean Iba-1 and GFAP luminance	48918
the stumps relative to the lesion core	48951
the stumps	48951
the lesion core	48974
FB-treated spinal cords	48991
2 weeks	49015
postinjury	49023
a greater difference in mean Iba-1 luminance	49038
a greater difference	49038
mean Iba-1 luminance	49062
OEC-treated spinal cords	49088
a finding	49114
higher levels of immune cell infiltration	49140
higher levels	49140
immune cell infiltration	49157
the stumps of FB-treated rats	49187
the stumps	49187
FB-treated rats	49201
Fig. 7E ; FB 1.9 0.5 vs OEC 0.5 0.3 , p 0.0031	49218
Fig. 7E	49218
FB 1.9 0.5 vs OEC 0.5 0.3 , p 0.0031	49227
FB 1.9 0.5	49227
FB	49227
1.9 0.5	49230
OEC 0.5 0.3 , p 0.0031	49241
OEC 0.5 0.3	49241
OEC	49241
p 0.0031	49256
the Iba-1 luminance	49284
differences in mean GFAP luminance	49305
differences	49305
mean GFAP luminance	49320
FB - and OEC-treated rats	49376
FB	49376
OEC-treated rats	49384
Fig. 7F	49417
Our findings	49427
the relationship between scar border formation and immune cell infiltration	49450
the relationship	49450
scar border formation and immune cell infiltration	49475
scar border formation	49475
immune cell infiltration	49501
We	49527
OECs	49540
the astroglial scar	49565
immune cell activation and infiltration	49596
immune cell activation	49596
infiltration	49623
FBs	49650
Immunosuppression using cyclosporine-A	49655
Immunosuppression	49655
cyclosporine-A	49679
graft cell survival	49703
We	49723
OECs	49736
the host immune response at 2 but not 8 weeks postinjury and suspect	49750
the host immune response at 2	49750
the host immune response	49750
2	49778
8 weeks postinjury and suspect	49788
8 weeks	49788
this loss at 8 weeks	49824
this loss	49824
8 weeks	49837
immune-mediated rejection of the transplanted cells	49855
immune-mediated rejection	49855
the transplanted cells	49884
immunosuppression	49929
OEC survival	49961
CSA	49975
the rats	49999
the study	50030
CSA treatment	50041
the survival of both FBs and OECs	50064
the survival	50064
both FBs and OECs	50080
2 and 8 weeks -LRB- Table 1 -RRB-	50101
2 and 8 weeks	50101
Table 1	50116
More transplanted cells in CSA-treated rats	50126
More transplanted cells	50126
CSA-treated rats	50153
the lesion core at 2 weeks	50184
the lesion core	50184
2 weeks	50203
our findings	50225
non-immunosuppressed rats	50241
Figs. 8A , B , 1C , D	50276
Figs. 8A	50276
B	50285
1C	50288
D	50291
2 weeks	50298
FBs and OECs in CSA-treated -LRB- FB CSA ; OEC CSA -RRB- rats	50307
FBs and OECs	50307
CSA-treated -LRB- FB CSA ; OEC CSA -RRB- rats	50323
FB CSA ; OEC CSA	50336
FB CSA	50336
OEC CSA	50344
the lesion core -LRB- Fig. 8E ; FB84 10 % , OEC75 4 % -RRB-	50372
the lesion core	50372
Fig. 8E ; FB84 10 % , OEC75 4 %	50389
Fig. 8E	50389
FB84 10 % , OEC75 4 %	50398
FB84 10 %	50398
FB84	50398
OEC75 4 %	50407
OEC75	50407
The CSA treatment	50418
the percentage	50460
the lesion volume	50478
FBs -LRB- 29 12 % -RRB- and OECs -LRB- 41 8 % -RRB-	50506
FBs	50506
29 12 %	50511
OECs	50525
41 8 %	50531
non-CSA-treated rats	50554
2 weeks -LRB- FB 3 3 % , p 0.0131 ; OECs1 0.1 % , p 0.0007 -RRB-	50578
2 weeks	50578
FB 3 3 % , p 0.0131 ; OECs1 0.1 % , p 0.0007	50587
FB 3 3 %	50587
FB	50587
p 0.0131 ; OECs1 0.1 %	50596
p 0.0131	50596
OECs1 0.1 %	50606
OECs1	50606
p 0.0007	50618
p	50618
0.0007	50620
8 weeks	50632
postinjury CSA-treated rats	50640
both cell types	50678
the lesion core	50707
Table 1 ; Fig. 8C , D , E ; FB48 27 % , OEC14 8 % , p 0.0241	50724
Table 1 ; Fig. 8C , D , E ; FB48 27 %	50724
Table 1	50724
Table	50724
1	50730
Fig. 8C , D , E	50733
Fig. 8C	50733
D	50741
E	50743
FB48 27 %	50746
FB48	50746
27 %	50751
OEC14 8 %	50755
OEC14	50755
p 0.0241	50765
p	50765
0.0241	50767
both	50780
bridges between the rostralandcaudal stumps -LRB- Fig. 8C , D -RRB-	50792
bridges	50792
the rostralandcaudal stumps -LRB- Fig. 8C , D -RRB-	50808
the rostralandcaudal stumps	50808
Fig. 8C , D	50837
Fig. 8C	50837
D	50845
the non-CSA-treated rats at 8 weeks	50861
the non-CSA-treated rats	50861
8 weeks	50889
CSA treatment	50898
a limited percentage	50922
transplanted cells in the lesion core -LRB- FB 8 9 % ; OEC 4 3 % -RRB-	50946
transplanted cells	50946
the lesion core -LRB- FB 8 9 % ; OEC 4 3 % -RRB-	50968
the lesion core	50968
FB 8 9 % ; OEC 4 3 %	50985
FB	50985
8 9 % ; OEC 4 3 %	50988
8 9 %	50988
OEC 4 3 %	50995
OEC	50995
enhanced cell survival	51021
suppression of the innate immune response	51055
suppression	51055
the innate immune response	51070
CSA administration	51103
we	51123
Iba-1 luminance levels	51135
Figure 6A	51164
CSA	51175
Iba-1 levels	51187
both transplant groups	51203
2 and 8 weeks postinjury , with a greater reduction in FB -	51229
2 and 8 weeks	51229
postinjury	51243
a greater reduction in FB	51260
a greater reduction	51260
FB	51283
OEC-treated rats	51292
We	51310
immune cell infiltration	51327
the difference in mean Iba-1 luminance	51365
the difference	51365
mean Iba-1 luminance	51383
the stumps and lesion core of transplanted rats	51407
the stumps and lesion core	51407
transplanted rats	51437
both cell transplants	51459
immune cell infiltration	51482
CSA treatment at 2	51534
CSA treatment	51534
2	51551
8 weeks	51565
Fig. 8F	51574
2 week FB CSA 0.6 0.1	51583
2 week FB CSA	51583
0.6 0.1	51599
OEC CSA 0.2 0.1 ; 8 week FB CSA 0.6 0.4 vs OEC CSA 0.2 0.1	51612
OEC CSA 0.2 0.1	51612
OEC CSA	51612
8 week FB CSA 0.6 0.4 vs OEC CSA 0.2 0.1	51634
8 week FB CSA 0.6 0.4	51634
8 week FB CSA	51634
0.6 0.4	51650
OEC CSA 0.2 0.1	51663
OEC CSA	51663
CSA treatment	51700
Iba-1 luminance levels of FB	51722
Iba-1 luminance levels	51722
FB	51748
not OEC-treated rats	51756
their non-CSA controls	51791
Fig. 8F ; FB 1.9 0.5 vs FB CSA 0.6 0.1 , p 0.0121	51815
Fig. 8F	51815
FB 1.9 0.5 vs FB CSA 0.6 0.1 , p 0.0121	51824
FB 1.9 0.5	51824
FB	51824
1.9 0.5	51827
FB CSA 0.6 0.1 , p 0.0121	51838
FB CSA	51838
0.6 0.1 , p 0.0121	51845
0.6 0.1	51845
p 0.0121	51854
These results	51865
CSA administration	51892
the innate immune response	51919
spinal cord transection	51952
the survival of both FBs and OECs	51990
the survival	51990
both FBs and OECs	52006
the 2-week time point	52027
Enhanced-OEC survival	52050
preservation of neurons and axons	52081
preservation	52081
neurons and axons	52097
CSA-enhanced OEC survival	52136
a beneficial response	52171
we	52194
neuronal preservation	52212
2 weeks	52238
neurons	52246
the astroglial scar border	52274
CSA treatment -LRB- Fig. 9A -RRB-	52307
CSA treatment	52307
Fig. 9A	52322
The neuron-free distance	52332
the total distance between rostral and caudal stump neurons	52361
the total distance	52361
rostral and caudal stump neurons	52388
the FB and OEC groups	52440
CSA administration	52468
both 2 and 8 weeks -LRB- CSA data not shown -RRB-	52490
both 2 and 8 weeks	52490
CSA data not shown	52510
CSA data	52510
the extent of tissue preservation in the stumps	52540
the extent	52540
tissue preservation in the stumps	52554
tissue preservation	52554
the stumps	52577
CSAenhanced OEC survival	52608
neurons now	52634
neurons	52634
the GFAPnegative lesion core of OEC	52658
the GFAPnegative lesion core	52658
OEC	52690
CSA-treated rats at 2	52694
CSA-treated rats	52694
2	52714
4 weeks in non-CSA-treated rats -LRB- compare Figs. 9B , 2B -RRB-	52728
4 weeks	52728
non-CSA-treated rats	52739
Figs. 9B , 2B	52769
Figs. 9B	52769
2B	52779
we	52789
axons	52801
the lesion core	52825
OECs	52850
8 weeks	52867
injury and CSA treatment	52881
Bundles of OECs	52907
Bundles	52907
OECs	52918
neurofilament-labeled axons	52934
the scar border	52981
our 4-week observation -LRB- Fig. 3F -RRB-	53013
our 4-week observation	53013
Fig. 3F	53037
axons	53059
OECs in the lesion core	53101
OECs	53101
the lesion core	53109
8 weeks -LRB- Fig. 9C -RRB-	53128
8 weeks	53128
Fig. 9C	53137
Confocal 3D visualization	53147
OECs	53179
axons	53207
both horizontal -LRB- Fig. 9C , white arrows -RRB-	53216
both horizontal	53216
Fig. 9C , white arrows	53233
Fig. 9C	53233
white arrows	53242
cross-sectional -LRB- Fig. 9C , white arrowhead -RRB- orientation	53260
Fig. 9C	53277
white arrowhead	53286
It	53316
OECs	53346
a bridge for axons to grow into the lesion core ,	53368
a bridge	53368
axons to grow into the lesion core ,	53381
the lesion core	53400
some functionally supportive role	53435
the lesion core	53476
OEC CSA treatment	53493
5-HT axon protection from dieback	53520
5-HT axon protection	53520
dieback	53546
enhanced FB or OEC survival due to CSA treatment	53572
enhanced FB or OEC survival	53572
CSA treatment	53607
axons	53636
axon regeneration	53654
we	53673
raphespinal tract axons	53687
-LRB- 1 -RRB- the number of axons that crossed the border	53725
the number	53729
axons that crossed the border	53743
axons	53743
the border	53762
-LRB- 2 -RRB- the area in the lesion core that contains 5-HT axons	53774
the area	53778
the lesion core that contains 5-HT axons	53790
the lesion core	53790
5-HT axons	53820
the distance	53840
the rostral border to the furthest extending 5-HT axon	53858
the rostral border	53858
the furthest extending 5-HT axon	53880
the furthest	53880
5-HT axon	53903
Fig. 9D ` ÄìF	53914
Fig. 9D	53914
` ÄìF	53921
non-immunosuppressed rats	53940
CSA treatment	53967
the number	53990
5-HT axons	54004
the rostral astrocyte scar border	54028
FB - and OEC-treated rats	54065
2 weeks -LRB- Fig. 9D ; FB + CSA 34	54093
2 weeks	54093
Fig. 9D	54102
FB + CSA 34	54111
FB	54111
CSA 34	54116
21	54124
p = 0.0314 ; OEC+CSA 86 ¬	54128
p = 0.0314 ; OEC+CSA 86	54128
p = 0.0314	54128
p	54128
0.0314	54130
OEC+CSA 86	54138
9 axons	54150
p = 0.0023	54159
p	54159
0.0023	54161
8 weeks	54173
CSA + OEC treatment	54182
CSA	54182
OEC treatment	54188
a twofold greater number	54211
5-HT axons	54239
the border compared with OEC-treatment alone -LRB- Fig. 9D ; OEC + CSA 46 ¬	54263
the border	54263
OEC-treatment alone -LRB- Fig. 9D ;	54288
OEC-treatment alone	54288
Fig. 9D	54309
OEC + CSA 46 ¬	54318
OEC + CSA 46	54318
OEC	54318
CSA 46	54324
18	54334
p = 0.0487	54338
p	54338
0.0487	54342
We	54351
larger areas	54360
5-HT-positive axons	54376
the lesion core	54399
CSA	54418
non-CSA-treated rats	54427
both transplant groups at 2 weeks -LRB- Fig. 9E ; FB + CSA 19,718 ¬	54451
transplant groups at 2 weeks -LRB- Fig. 9E ; FB + CSA 19,718 ¬	54456
transplant groups	54456
2 weeks -LRB- Fig. 9E ; FB + CSA 19,718	54477
2 weeks	54477
Fig. 9E	54486
FB + CSA 19,718	54495
FB	54495
CSA 19,718	54500
5707 ¬ µm2	54514
p = 0.0020 ; OEC + CSA 33,013	54525
p = 0.0020	54525
p	54525
0.0020	54529
OEC + CSA 33,013	54537
OEC	54537
CSA 33,013	54543
8295 ¬ µm2 , p = 0.0018 -RRB-	54557
8295 ¬ µm2	54557
p = 0.0018	54568
p	54568
0.0018	54572
Surpris	54581
the distance	54597
the furthest	54613
5-HT axon increased in the FB	54636
5-HT axon	54636
the FB	54659
OEC-treated rats	54675
2 weeks with CSA administration -LRB- Fig. 9F ; FB 371 ¬ ± 161 vs FB+CSA 146	54695
2 weeks with CSA administration -LRB- Fig. 9F ; FB 371 ¬ ±	54695
2 weeks	54695
CSA administration -LRB- Fig. 9F ; FB 371 ¬	54708
CSA	54708
administration -LRB- Fig. 9F ; FB 371 ¬	54712
administration -LRB- Fig. 9F ; FB 371	54712
administration	54712
Fig. 9F ; FB 371	54728
Fig. 9F	54728
FB 371	54737
161 vs FB+CSA 146	54746
161	54746
FB+CSA 146	54753
± 84 ¬ µm	54764
p = 0.0018	54772
p	54772
0.0018	54775
8 weeks	54791
5-HT-positive axons	54800
the lesion core of OEC + CSA than FB	54842
the lesion core of OEC	54842
the lesion core	54842
OEC	54861
CSA than FB	54866
CSA	54866
FB	54875
CSA-treated rats	54880
Fig. 9F ; FB + CSA -117 ¬ ± 166 vs OEC ¬ ± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54898
Fig. 9F ; FB	54898
Fig. 9F	54898
FB	54907
CSA -117 ¬ ± 166 vs OEC ¬ ± CSA 361 ¬ ± 137 ¬ µm , p = 0.0089	54912
CSA -117 ¬ ±	54912
166 vs OEC	54925
166	54925
OEC	54932
CSA	54939
361 ¬	54943
361	54943
± 137 ¬ µm ,	54948
± 137 ¬ µm	54948
± 137 ¬	54948
µm	54955
CSA treatment	54978
5-HT axon preservation	55001
FB-treated rats	55027
2 weeks postinjury	55051
these results	55081
OEC transplantation	55109
the extension of 5-HT axons	55138
the extension	55138
5-HT axons	55155
the scar border	55173
CSA-enhanced survival of OECs	55198
CSA-enhanced survival	55198
OECs	55223
these axons in the lesion core	55238
these axons	55238
the lesion core	55253
Enhanced-OEC and FB survival	55277
Enhanced-OEC	55277
FB survival	55294
inhibitory factors	55314
the injury site	55336
CSA-enhanced OEC survival	55368
inhibitory factors in the lesion site	55405
inhibitory factors	55405
the lesion site	55427
that observed with non-CSA-treated rats	55450
that	55450
non-CSA-treated rats	55469
we	55491
CSPG	55503
luminance levels in the lesion core and the rostral and caudal stumps	55508
luminance levels in the lesion core	55508
luminance levels	55508
the lesion core	55528
the rostral and caudal stumps	55548
the rostral	55548
caudal stumps	55564
We	55579
a time-dependent CSA treatment effect	55591
the levels of CSPG luminance	55632
the levels	55632
CSPG luminance	55646
the lesion core	55664
transplant groups	55685
2 week CSA 2.7 ¬ ± 0.3 vs no CSA 2.3 ¬ ± 0.2	55718
2 week CSA 2.7 ¬ ±	55718
2	55718
week CSA 2.7 ¬ ±	55720
week CSA 2.7 ¬	55720
week	55720
CSA 2.7 ¬	55725
CSA 2.7	55725
CSA	55725
2.7	55729
0.3 vs no CSA 2.3 ¬ ± 0.2	55734
0.3 vs	55734
no CSA 2.3 ¬ ± 0.2	55741
no CSA 2.3 ¬	55741
no	55741
CSA 2.3 ¬	55744
CSA 2.3	55744
CSA	55744
2.3	55748
0.2	55753
p = 0.0444 ; 8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7 ¬ ± 0.5	55758
p	55758
0.0444 ; 8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7 ¬ ± 0.5	55760
0.0444 ; 8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7 ¬	55760
0.0444	55760
; 8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7 ¬	55766
; 8 week CSA 1.9 ¬ ± 0.2 vs no CSA 2.7	55766
8 week CSA 1.9 ¬ ± 0.2	55768
8	55768
week CSA 1.9 ¬ ± 0.2	55770
week CSA 1.9 ¬	55770
week	55770
CSA 1.9 ¬	55775
CSA 1.9	55775
CSA	55775
1.9	55779
0.2	55784
no CSA 2.7	55791
no CSA	55791
2.7	55798
0.5	55804
p = 0.0156	55809
p	55809
0.0156	55813
the stumps	55833
the lesion core	55848
CSPG levels	55865
higher	55886
FB + CSA	55896
FB	55896
CSA	55901
OEC + CSA groups	55919
2 and 8 weeks -LRB- Fig. 9H ; 2 weeks , p = 0.0008 ; 8 weeks , p = 0.0438 -RRB-	55939
2 and 8 weeks	55939
Fig. 9H ; 2 weeks , p = 0.0008 ; 8 weeks , p = 0.0438	55954
Fig. 9H	55954
2 weeks , p = 0.0008 ; 8 weeks , p = 0.0438	55963
2 weeks	55963
p = 0.0008 ; 8 weeks , p = 0.0438	55972
p = 0.0008	55972
p	55972
0.0008	55974
8 weeks , p = 0.0438	55982
8 weeks	55982
p = 0.0438	55991
p	55991
0.0438	55994
2 weeks , however	56006
2 weeks	56006
spinal rats	56024
OEC	56049
CSA	56056
higher CSPG levels in the lesion core	56064
higher CSPG levels	56064
the lesion core	56086
those treated with OECs alone -LRB- Fig. 9H ; OEC 1.2 ¬ ± 0.1 vs OEC+CSA 2.1 ¬	56107
those	56107
OECs alone -LRB- Fig. 9H ; OEC 1.2 ¬ ±	56126
OECs	56126
alone -LRB- Fig. 9H ; OEC 1.2 ¬ ±	56131
alone -LRB- Fig. 9H ; OEC 1.2 ¬	56131
alone	56131
Fig. 9H ; OEC 1.2 ¬	56138
Fig.	56138
9H ; OEC 1.2 ¬	56143
9H ; OEC 1.2	56143
9H	56143
OEC 1.2	56147
0.1 vs OEC+CSA 2.1 ¬	56156
0.1 vs OEC+CSA 2.1	56156
0.1	56156
OEC+CSA 2.1	56163
0.3	56176
p = 0.0144	56181
p	56181
= 0.0144	56182
CSPG levels in the lesion core	56193
CSPG levels	56193
the lesion core	56208
FB	56238
with FB-treated rats at 8 weeks -LRB- Fig. 9H ; FB 3.9 ¬ ± 0.5 vs FB + CSA 2.4 ¬	56255
with FB-treated rats at 8 weeks -LRB- Fig. 9H ; FB 3.9 ¬ ± 0.5 vs FB + CSA 2.4	56255
with FB-treated rats at 8 weeks -LRB- Fig. 9H ; FB 3.9 ¬ ± 0.5	56255
with FB-treated rats at 8 weeks -LRB- Fig. 9H ; FB 3.9 ¬ ±	56255
with FB-treated rats	56255
8 weeks -LRB- Fig. 9H ; FB 3.9 ¬	56279
8	56279
weeks -LRB- Fig. 9H ; FB 3.9 ¬	56281
weeks -LRB- Fig. 9H ; FB 3.9	56281
weeks	56281
Fig. 9H ; FB 3.9	56288
Fig. 9H	56288
FB 3.9	56297
0.5	56307
FB + CSA 2.4	56314
FB	56314
CSA 2.4	56319
0.1	56328
p = 0.0059	56333
p	56333
0.0059	56335
CSPG levels in the stump borders	56344
CSPG levels	56344
the stump borders	56359
FB + CSA groups	56397
OEC + CSA groups	56427
both time points	56447
Fig. 9I ; 2 weeks , p = 0.0326 ; 8 weeks , p = 0.0460	56465
Fig. 9I	56465
2 weeks , p = 0.0326 ; 8 weeks , p = 0.0460	56474
2 weeks	56474
p = 0.0326 ; 8 weeks , p = 0.0460	56483
p = 0.0326	56483
p	56483
0.0326	56485
8 weeks , p = 0.0460	56493
8 weeks	56493
p = 0.0460	56502
p	56502
0.0460	56505
These findings	56514
OECs	56540
CSPG levels	56552
time at the lesion site regardless of CSA treatment	56569
time	56569
the lesion site regardless of CSA treatment	56577
the lesion site	56577
CSA treatment	56607
We	56622
levels of Oil Red O staining in FB ¬ ± CSA	56648
levels of Oil Red O staining in FB ¬ ±	56648
levels	56648
Oil Red O staining in FB ¬	56658
Oil Red O staining	56658
FB	56680
OEC + CSA-treated injury sites	56695
OEC	56695
CSA-treated injury sites	56701
immunosuppression	56741
the presence of myelin debris	56767
the presence	56767
myelin debris	56783
a reduction in myelin debris	56807
a reduction	56807
myelin debris	56822
CSA	56852
non-CSA-treated spinal cords	56870
the cell transplant type	56913
Figs. 10A ` ÄìD , 5A , B , E , F	56947
Figs. 10A	56947
ÄìD , 5A , B , E , F	56957
Punctate Oil Red O-stained debris	56973
8 week FB - and OEC-treated spinal cords -LRB- Fig. 10c , d -RRB-	57023
8 week FB	57023
OEC-treated spinal cords	57038
Fig. 10c	57064
d	57073
FB-treated rats	57084
myelin debris	57101
the lesion core	57128
the GFAP-positive stumps at 2 and 8 weeks -LRB- Fig. 10A , C -RRB-	57167
the GFAP-positive stumps	57167
2 and 8 weeks -LRB- Fig. 10A , C -RRB-	57195
2 and 8 weeks	57195
Fig. 10A , C	57210
Fig. 10A	57210
C	57219
contrast	57226
OEC + CSA-treated rats	57236
OEC	57236
CSA-treated rats	57242
minimal myelin debris	57269
the lesion core and stumps -LRB- Fig. 10B , D -RRB-	57294
the lesion core	57294
stumps -LRB- Fig. 10B , D -RRB-	57314
stumps	57314
Fig. 10B , D	57322
Fig. 10B	57322
D	57331
the greater reduction	57342
myelin debris in OEC - compared with FB-treated rats after immunosuppression	57367
myelin debris	57367
OEC	57384
FB-treated rats after immunosuppression	57403
FB-treated rats	57403
immunosuppression	57425
we	57444
OECs	57456
the clearance of myelin	57478
the clearance	57478
myelin	57495
OECs	57528
myelin particles	57546
we	57564
OECs	57601
Confocal images	57607
MBP-positive myelin fragments	57632
the cytoplasm of OECs -LRB- Fig. 10E -RRB-	57669
the cytoplasm	57669
OECs -LRB- Fig. 10E -RRB-	57686
OECs	57686
Fig. 10E	57692
This observation	57703
OEC phagocytic activity	57734
the removal of inhibitory myelin debris postinjury	57781
the removal	57781
inhibitory myelin debris postinjury	57796
Discussion Spinal cord injury	57834
Discussion	57834
Spinal cord injury	57845
a temporally regulated , pathological cascade	57873
cellular changes	57921
both central and peripheral cells	57951
a layered scar	57996
an inhibitory environment	58022
the lesion site	58051
Burda and Sofroniew , 2014 ; Cregg et al. , 2014	58068
Burda and Sofroniew	58068
2014 ; Cregg et al.	58089
2014	58089
Cregg et al.	58095
Cregg	58095
et al.	58101
2014	58109
The present study	58116
FBs andOECsdiffer in their modification of the lesion site	58145
FBs andOECsdiffer	58145
their modification of the lesion site	58166
their modification	58166
the lesion site	58188
complete spinal cord transection	58210
OECs , but not FBs ,	58244
OECs	58244
FBs	58258
neurons and 5-HT axons in the lesion core	58281
neurons	58281
5-HT axons in the lesion core	58293
5-HT axons	58293
the lesion core	58307
inhibitory CSPGs and myelin debris	58331
inhibitory CSPGs	58331
myelin debris	58352
immune cell infiltration to reduce secondary tissue damage	58377
secondary tissue damage	58412
CSA	58442
OEC survival	58466
the innate immune response and secondary tissue damage	58480
the innate immune response	58480
secondary tissue damage	58511
The prolonged presence of OECs	58549
The prolonged presence	58549
OECs	58575
the survival of neurons	58589
the survival	58589
neurons	58605
the regeneration of axons in the lesion site	58629
the regeneration	58629
axons in the lesion site	58649
axons	58649
the lesion site	58658
contact-mediated mechanisms	58677
Our results	58706
evidence	58726
OECs	58740
axon regeneration	58774
a growth	58805
permissive substrate	58814
the inhospitable lesion site environment	58847
OECs	58889
astroglial scar border formation	58905
injury astrocytes	58944
a protective barrier	58967
further cell loss	59020
the spread of inflammation	59048
the spread	59048
inflammation	59062
blood	59088
Äìbrain barrier repair -LRB- Bush et al. , 1999 ; Faulkner et al. , 2004 -RRB-	59094
Äìbrain barrier repair	59094
Bush	59118
et al. , 1999 ; Faulkner et al. , 2004	59123
et al.	59123
1999 ; Faulkner et al.	59131
1999	59131
Faulkner et al.	59137
Faulkner	59137
et al.	59146
2004	59154
We	59161
FBs , but not OECs ,	59174
FBs	59174
OECs	59187
astrocyte barrier formation	59199
FB-transplanted rats	59236
greater cell infiltration and overall tissue damage	59262
greater cell infiltration	59262
overall tissue damage	59292
rats transplanted with OECs	59319
rats	59319
OECs	59342
Reactive astrocyte processes in FB-treated rats	59348
Reactive astrocyte processes	59348
FB-treated rats	59380
immune cells	59438
fibroblasts , or CSPG-positive cells within the spinal cord stumps	59461
fibroblasts	59461
CSPG-positive cells within the spinal cord stumps	59477
CSPG-positive cells	59477
the spinal cord stumps	59504
transplantation of skin FBs into the injured spinal cord	59534
transplantation	59534
skin FBs into the injured spinal cord	59553
skin FBs	59553
the injured spinal cord	59567
the amount of cellular invasion	59603
the amount	59603
cellular invasion	59617
the astrocytic scar formation	59655
contrast to FBs	59689
contrast	59689
FBs	59701
OECs	59706
astrocytes	59729
sequestration of invading peripheral cells	59767
sequestration	59767
peripheral cells	59793
example	59815
immune cell infiltration	59824
2 weeks	59859
FB	59870
4 weeks	59888
OECtreated rats	59899
our findings	59932
OECs	59946
astrocytes in vivo	59982
astrocytes	59982
vivo	59996
astrocyte reactivity or an increase	60019
astrocyte reactivity	60019
an increase	60043
CSPG levels	60058
transplantation	60080
intact spinal cords -LRB- Lakatos et al. , 2000 , 2003 -RRB-	60101
intact spinal cords	60101
Lakatos	60122
et al. , 2000 , 2003	60130
et al.	60130
2000	60138
2003	60144
OECs	60170
an in vitro scar-like culture model	60189
an in vitro scar-like culture	60189
scar-like culture	60201
they	60225
astrocytic reactivity	60244
the boundary zones	60278
meningeal fibroblasts -LRB- Khankan et al. , 2015 -RRB-	60316
meningeal fibroblasts	60316
Khankan	60339
et al. , 2015	60347
et al.	60347
2015	60355
OECs	60373
scar-forming astrocytes	60393
the lesion core following spinal cord injury	60427
the lesion core	60427
spinal cord injury	60453
Thus OECs , compared with FBs ,	60473
Thus OECs	60473
FBs	60498
reactive astrocyte border formation	60514
the re-establishment of the glial limitans	60572
the re-establishment	60572
the glial limitans	60596
The STAT3-signaling pathway	60616
the organization of reactive astrocyte processes	60659
the organization	60659
reactive astrocyte processes	60679
cells -LRB- Herrmann et al. , 2008 -RRB-	60726
cells	60726
Herrmann	60733
et al. , 2008	60742
et al.	60742
2008	60750
STAT3-null mice	60757
a deficient astrocytic scar barrier	60778
spinal cord injury	60820
increased inflammation	60855
neuronal loss -LRB- Herrmann et al. , 2008 ; Wanner et al. , 2013 -RRB-	60882
neuronal loss	60882
Herrmann	60897
et al. , 2008 ; Wanner et al. , 2013	60906
et al.	60906
2008 ; Wanner et al.	60914
2008	60914
Wanner et al.	60920
Wanner	60920
et al.	60927
2013	60935
our FB-treated spinal cords	60964
Reactive astrocytes	60993
Iba-1-positive inflammatory cells and CSPG-positive meningeal fibroblasts	61031
Iba-1-positive inflammatory cells	61031
CSPG-positive meningeal fibroblasts	61069
FB	61108
OECtreated rats	61121
The cytokines	61138
the activation of the tripartite receptor complex involved in STAT3-signaling	61172
the activation	61172
the tripartite receptor complex involved in STAT3-signaling	61190
the tripartite receptor complex	61190
STAT3-signaling	61234
CNTF , LIF , and IL-6 -LRB- Stahl and Yancopoulos , 1994 -RRB-	61254
CNTF , LIF ,	61254
CNTF	61254
LIF	61260
IL-6 -LRB- Stahl and Yancopoulos , 1994 -RRB-	61269
IL-6	61269
Stahl and Yancopoulos	61275
1994	61298
OECs	61332
Wewetzer et al. , 2001 ; Asan et al. , 2003 ; Herbert et al. , 2012	61338
Wewetzer	61338
et al. , 2001 ; Asan et al. , 2003 ; Herbert et al. , 2012	61347
et al. , 2001	61347
et al.	61347
2001	61355
Asan et al. , 2003	61361
Asan	61361
et al. , 2003	61366
et al.	61366
2003	61374
Herbert et al. , 2012	61380
Herbert	61380
et al. , 2012	61388
et al.	61388
2012	61396
cytokine signaling	61418
olfactory bulbectomy -LRB- Nan et al. , 2001 -RRB-	61443
olfactory bulbectomy	61443
Nan	61465
et al. , 2001	61469
et al.	61469
2001	61477
The CNTF , LIF , and IL-6 receptors	61484
The CNTF	61484
LIF	61494
IL-6 receptors	61503
an OEC-mediated regulatory role	61539
cytokine secretion -LRB- Nan et al. , 2001 ; Wewetzer et al. , 2001 -RRB-	61574
cytokine secretion	61574
Nan	61594
et al. , 2001 ; Wewetzer et al. , 2001	61598
et al.	61598
2001 ; Wewetzer et al.	61606
2001	61606
Wewetzer et al.	61612
Wewetzer	61612
et al.	61621
2001	61629
OECs	61642
astrocytes	61681
immune cell infiltration and secondary tissue damage	61701
activation of the STAT3 pathway	61758
activation	61758
the STAT3 pathway	61772
OECs	61791
immunomodulatory and neuroprotective Beck	61800
et al. -LRB- 2010 -RRB-	61842
et al.	61842
2010	61850
flow cytometry	61861
there	61904
a time-dependent , multiphasic inflammatory response in which	61913
a time-dependent , multiphasic inflammatory response	61913
macrophages	61974
first peak at 7 d and then at 60 d	61986
first peak	61986
7 d	62000
60 d	62016
a spinal cord contusion	62027
complete spinal cord transection	62058
the activation and peak of immune response	62092
the activation and peak	62092
immune response	62119
OEC	62150
FB-treated rats	62162
This delay in immune activation	62179
This delay	62179
immune activation	62193
the prolonged survival of OECs	62235
the prolonged survival	62235
OECs	62261
FBs	62280
OECs	62291
inflammation	62315
the injury site	62331
macrophage infiltration	62359
myelin debris	62393
neurons	62423
the scar border	62440
It	62457
OECs	62475
neurons in the lesion core	62488
neurons	62488
the lesion core	62499
a contact-mediated mechanism	62520
these neurons	62568
OECs	62610
This	62616
OECs	62635
neurons	62661
the astrocyte scar border	62684
CSA	62711
a potent immunosuppressant	62716
T-cell activation	62755
other immune cells -LRB- Ho et al. , 1996 -RRB-	62787
other immune cells	62787
Ho	62807
et al. , 1996	62810
et al.	62810
1996	62818
Iba-1 infiltration	62833
FB - and OEC-treated rats	62855
equivalent levels and prolonged FB and OEC survival in the lesion core	62883
equivalent levels	62883
prolonged FB and OEC survival in the lesion core	62905
prolonged FB and OEC survival	62905
the lesion core	62938
neurons	62959
the lesion core of OEC CSA , but not FB CSA-treated rats	62981
the lesion core of OEC CSA	62981
the lesion core	62981
OEC CSA	63000
FB CSA-treated rats	63019
FB	63019
CSA-treated rats	63024
This	63042
OECs	63061
neurons	63075
a different mechanism than CSA	63086
a different mechanism	63086
CSA	63113
an additive neuroprotective effect	63134
the combined use of OEC transplantation and CSA treatment	63174
the combined use	63174
OEC transplantation and CSA treatment	63194
OEC transplantation	63194
CSA treatment	63218
the OEC-mediated delay and attenuation of immune infiltration	63244
the OEC-mediated delay and attenuation	63244
immune infiltration	63286
secondary tissue damage	63314
the direct presence of OECs	63362
the direct presence	63362
OECs	63385
neurons	63401
the lesion core	63412
OECs	63429
5-HT axonal loss	63440
Our data	63457
OEC-mediated immunomodulation and direct OEC-axon alignment	63474
potential mechanisms	63537
5-HT axons	63574
the lesion core	63588
Evans et al. -LRB- 2014 -RRB-	63605
Evans et al.	63605
Evans	63605
et al.	63611
2014	63619
blood-derived macrophages	63649
axonal dieback in a dorsal column crush model of spinal cord injury	63695
axonal dieback	63695
a dorsal column crush model of spinal cord injury	63713
a dorsal column crush model	63713
spinal cord injury	63744
we	63775
more 5-HT axonal dieback	63787
OEC-treated rats	63831
the peak time of immune infiltration	63851
the peak time	63851
immune infiltration	63868
CSA	63889
5-HT axonal preservation in FB-treated rats only at the 2 week time point	63917
5-HT axonal preservation	63917
FB-treated rats only at the 2 week time point	63945
FB-treated rats	63945
the 2 week time point	63969
the axonal dieback caused by immune infiltration	64003
the axonal dieback	64003
immune infiltration	64032
no 5-HT axonal dieback	64065
OEC-treated rats	64104
CSA treatment	64137
OECs in the lesion core	64168
OECs	64168
the lesion core	64176
5-HT axon preservation via contact-mediated mechanisms , independent of CSA	64203
5-HT axon preservation	64203
contact-mediated mechanisms , independent of CSA	64230
contact-mediated mechanisms	64230
independent of CSA	64259
independent	64259
CSA	64274
we	64290
alignment with OECs	64307
alignment	64307
OECs	64322
neurite outgrowth	64350
an in vitro scar-like culture model of spinal cord injury	64371
scar-like culture model of spinal cord injury	64383
scar-like culture model	64383
spinal cord injury	64410
Khankan	64430
et al. , 2015	64438
et al.	64438
2015	64446
OECs	64461
multiple axon guidance and adhesion molecules	64474
it	64521
these OEC-axonal interactions	64539
both orient axons	64573
their growth postinjury	64603
Both 5-HT and neurofilament-labeled axons	64628
Both 5-HT	64628
neurofilament-labeled axons	64642
palisading astrocytic processes	64683
the scar border	64735
OECs	64778
Interactions between transplanted OECs and scar-forming astrocytes	64784
Interactions	64784
transplanted OECs and scar-forming astrocytes	64805
transplanted OECs	64805
scar-forming astrocytes	64827
a surface	64867
axon regeneration	64891
an arrangement	64910
the ` Äúpathway	64938
hypothesis ` Äù	64953
neural repair -LRB- Li et al. , 2005b ; Raisman and Li , 2007 -RRB-	64970
neural repair	64970
Li	64985
et al. , 2005b ; Raisman and Li , 2007	64988
et al.	64988
2005b ; Raisman and Li	64996
2005b	64996
Raisman and Li	65003
2007	65019
the scar border OECs	65033
a trabecular network	65070
OEC-lined conduits surrounded by a fibronectin-rich matrix	65103
OEC-lined conduits	65103
a fibronectin-rich matrix	65136
OECs	65176
an olfactory nerve lesion -LRB- Li et al. , 2005a -RRB-	65187
an olfactory nerve lesion	65187
Li	65214
et al. , 2005a	65217
et al.	65217
2005a	65225
these conduits	65244
axons	65270
OEC transplantation	65299
structural scaffolds	65338
axon regeneration	65375
astrocyte bridges and OEC-lined conduits	65406
astrocyte bridges	65406
OEC-lined conduits	65428
OECs	65448
inhibitory CSPGs	65460
myelin debris postinjury A well known feature of the inhibitory glial scar	65481
myelin debris postinjury A	65481
feature of the inhibitory glial scar	65519
feature	65519
the inhibitory glial scar	65530
the upregulation and secretion	65559
CSPGs	65593
astrocytes and fibroblasts	65602
McKeon et al. , 1995 ; Morgenstern et al. , 2002 ; Fitch and Silver , 2008	65630
McKeon	65630
et al. , 1995 ; Morgenstern et al. , 2002 ; Fitch and Silver , 2008	65637
et al. , 1995	65637
et al.	65637
1995	65645
Morgenstern et al. , 2002	65651
Morgenstern	65651
et al. , 2002	65663
et al.	65663
2002	65671
Fitch and Silver , 2008	65677
Fitch and Silver	65677
2008	65695
Several studies	65702
OECs	65730
CSPG immunoreactivity	65742
the injured spinal cord	65767
Lakatos	65792
et al. , 2003 ; Barbour et al. , 2013	65800
et al.	65800
2003 ; Barbour et al.	65808
2003	65808
Barbour et al.	65814
Barbour	65814
et al.	65822
2013	65830
our 8 week data	65841
a direct correlation between the loss of OECs and the increase in CSPG density	65862
a direct correlation	65862
the loss of OECs and the increase in CSPG density	65891
the loss of OECs	65891
the loss	65891
OECs	65903
the increase in CSPG density	65912
the increase	65912
CSPG density	65928
addition to reducing inhibitory CSPGs	65945
addition	65945
inhibitory CSPGs	65966
OEC treatment	65984
the buildup of myelin debris	66006
the buildup	66006
myelin debris	66021
the lesion core and spinal cord stumps	66038
the lesion core	66038
spinal cord stumps	66058
The accumulation of myelin debris	66078
The accumulation	66078
myelin debris	66098
axon regeneration -LRB- Filbin , 2003 ; Yiu and He , 2006 -RRB-	66121
axon regeneration	66121
Filbin , 2003 ; Yiu and He , 2006	66140
Filbin	66140
2003 ; Yiu and He	66148
2003	66148
Yiu and He	66154
Yiu	66154
He	66162
2006	66166
secondary damage due to inflammation -LRB- Sun et al. , 2010 -RRB-	66187
secondary damage	66187
inflammation	66211
Sun	66225
et al. , 2010	66229
et al.	66229
2010	66237
OECs	66252
the inflammatory response , this reduction in myelin debris	66266
the inflammatory response	66266
this reduction in myelin debris	66293
this reduction	66293
myelin debris	66311
the decrease in inflammation	66339
the decrease	66339
inflammation	66355
OEC-treated rats	66378
lower levels of myelin debris	66405
lower levels	66405
myelin debris	66421
CSA administration	66441
OECs	66461
phagocytes	66470
apoptotic olfactory receptor axons	66497
Su et al. , 2013 ; Nazareth et al. , 2015	66533
Su et al.	66533
2013 ; Nazareth et al.	66544
2013	66544
Nazareth et al.	66550
Nazareth	66550
et al.	66559
2015	66567
We	66574
evidence	66589
OECs	66603
myelin particles	66619
myelin debris	66653
a complete spinal cord transection	66681
OECs likely	66734
OECs	66734
myelin debris	66769
Astrocytes and microglia/macrophages	66784
a traumatic injury	66832
complex molecular signaling cascades	66865
the responses of multiple neural and peripheral cells	66907
the responses	66907
multiple neural and peripheral cells	66924
both a chemical and mechanical barrier	66970
a chemical	66975
mechanical barrier	66990
regeneration	67017
OECs	67031
the astrocyte response	67047
astrocytic processes	67082
pathways that would enhance axon outgrowth	67114
pathways	67114
axon outgrowth	67142
Li	67158
et al. , 2005b ; current study	67161
et al.	67161
2005b	67169
current study	67176
the reduction in OEC survival	67200
the reduction	67200
OEC survival	67217
the number of 5-HT axons crossing the border	67231
the number	67231
5-HT axons crossing the border	67245
5-HT axons	67245
the border	67265
these axons	67300
the lesion core	67336
Such findings	67353
OECs	67390
the lesion microenvironment	67406
an early time point postinjury	67437
long lasting effects on axon regeneration	67484
long lasting effects	67484
axon regeneration	67508
survival of OECs	67536
survival	67536
OECs	67548
a bridge	67562
axons	67588
the scar border	67611
axons	67641
the lesion core	67650
later time points	67669
we	67702
OEC transplantation after a complete spinal cord transection	67718
OEC transplantation	67718
a complete spinal cord transection	67744
contact-associated mechanisms	67827
an environment that supports axonal regeneration	67867
an environment	67867
axonal regeneration	67896
